REVVITY, INC., 10-K filed on 2/25/2025
Annual Report
v3.25.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 29, 2024
Feb. 21, 2025
Jun. 28, 2024
Dec. 31, 2023
Jun. 30, 2023
Entity Listings [Line Items]          
Document Annual Report true        
Entity Well-known Seasoned Issuer Yes        
Entity Voluntary Filers No        
Entity Current Reporting Status Yes        
Entity Interactive Data Current Yes        
Entity Public Float     $ 12,871,238,120    
ICFR Auditor Attestation Flag true        
Entity Shell Company false        
Document Financial Statement Error Correction [Flag] false        
Sale of Stock, Price Per Share         $ 104.86
Common stock, par value $ 1     $ 1  
Document Type 10-K        
Document Period End Date Dec. 29, 2024        
Document Transition Report false        
Entity File Number 001-5075        
Entity Registrant Name REVVITY, INC.        
Entity Incorporation, State or Country Code MA        
Entity Tax Identification Number 04-2052042        
Entity Address, Address Line One 77 4th Avenue        
Entity Address, City or Town Waltham,        
Entity Address, State or Province MA        
Entity Address, Postal Zip Code 02451        
City Area Code 781        
Local Phone Number 663-6900        
Entity Current Reporting Status Yes        
Entity Interactive Data Current Yes        
Entity Filer Category Large Accelerated Filer        
Entity Small Business false        
Entity Emerging Growth Company false        
Entity Common Stock, Shares Outstanding   120,187,286      
Entity Central Index Key 0000031791        
Document Fiscal Year Focus 2024        
Document Fiscal Period Focus FY        
Amendment Flag false        
Current Fiscal Year End Date --12-29        
RVTY [Member]          
Entity Listings [Line Items]          
Trading Symbol RVTY        
Trading Symbol RVTY        
RVTY 26 [Member]          
Entity Listings [Line Items]          
Trading Symbol RVTY 26        
Trading Symbol RVTY 26        
Common stock, $1 par value per share [Member]          
Entity Listings [Line Items]          
Title of 12(b) Security Common Stock, $1 par value per share        
Title of 12(b) Security Common Stock, $1 par value per share        
1.875% Notes due 2026 [Member]          
Entity Listings [Line Items]          
Title of 12(b) Security 1.875% Notes due 2026        
Title of 12(b) Security 1.875% Notes due 2026        
NEW YORK STOCK EXCHANGE, INC. [Member]          
Entity Listings [Line Items]          
Security Exchange Name NYSE        
Security Exchange Name NYSE        
v3.25.0.1
Audit Information
 12 Months Ended
Dec. 29, 2024
Audit Information [Abstract]  
Auditor Name DELOITTE & TOUCHE LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 34
v3.25.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 29, 2024
Feb. 21, 2025
Jun. 28, 2024
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 29, 2024    
Document Transition Report false    
Entity File Number 001-5075    
Entity Registrant Name REVVITY, INC.    
Entity Central Index Key 0000031791    
Current Fiscal Year End Date --12-29    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Incorporation, State or Country Code MA    
Entity Tax Identification Number 04-2052042    
Entity Address, Address Line One 77 4th Avenue    
Entity Address, City or Town Waltham,    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 781    
Local Phone Number 663-6900    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 12,871,238,120
Entity Common Stock, Shares Outstanding   120,187,286  
Documents Incorporated by Reference
Portions of Revvity, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on April 22, 2025 are incorporated by reference into Part III of this Form 10-K.
    
Common stock, $1 par value per share [Member]      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $1 par value per share    
1.875% Notes due 2026 [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 1.875% Notes due 2026    
NEW YORK STOCK EXCHANGE, INC. [Member]      
Entity Information [Line Items]      
Security Exchange Name NYSE    
RVTY [Member]      
Entity Information [Line Items]      
Trading Symbol RVTY    
RVTY 26 [Member]      
Entity Information [Line Items]      
Trading Symbol RVTY 26    
v3.25.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Revenue      
Segment revenue $ 2,755,026 $ 2,750,571 $ 3,311,822
Segment selling, general and administrative expenses 994,074 1,022,551 1,025,514
Segment research and development expenses 196,844 216,578 221,617
Operating income from continuing operations 346,741 300,562 742,699
Interest and other expense, net 30,615 117,586 90,862
Income from continuing operations before income taxes 316,126 182,976 651,837
Provision for income taxes 33,055 3,473 139,161
Income from continuing operations 283,071 179,503 512,676
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest (12,686) 513,591 56,503
Net income $ 270,385 $ 693,094 $ 569,179
Basic earnings per share:      
Income from continuing operations $ 2.31 $ 1.44 $ 4.06
Income from discontinued operations and dispositions (0.10) 4.12 0.45
Net income 2.21 5.56 4.51
Diluted earnings per share:      
Income from continuing operations 2.30 1.44 4.06
Income from discontinued operations and dispositions (0.10) 4.11 0.45
Net income $ 2.20 $ 5.55 $ 4.50
Product [Member]      
Revenue      
Segment revenue $ 2,338,211 $ 2,415,893 $ 2,634,582
Cost of Goods and Services Sold 1,041,749 1,077,744 1,150,402
Service [Member]      
Revenue      
Segment revenue 416,815 334,678 677,240
Cost of Goods and Services Sold $ 175,618 $ 133,136 $ 171,590
v3.25.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Net income $ 270,385 $ 693,094 $ 569,179
Other comprehensive income (loss)      
Foreign currency translation adjustments, net of income taxes, recognized in other comprehensive income (119,260) 80,172 (284,854)
Foreign currency translation adjustments, net of income taxes, reclassified to earnings 0   0
Foreign currency translation adjustments, net of income taxes, recognized in discontinued operations   90,814  
Net foreign currency translation adjustments, net of income taxes (119,260) 170,986 (284,854)
Unrecognized prior service credit, net of tax 0 0 44
Unrealized (losses) gains on securities, net of tax (153) (181) 5
Other comprehensive (loss) income (119,413) 170,805 (284,805)
Comprehensive income $ 150,972 $ 863,899 $ 284,374
v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 1,163,396 $ 913,163
Marketable Securities, Current 0 689,916
Accounts receivable, net 632,400 632,811
Inventories 367,587 428,062
Other current assets 186,225 337,139
Total current assets 2,349,608 3,001,091
Property, plant and equipment, net 482,217 509,654
Operating Lease, Right-of-Use Asset 167,716 155,083
Intangible assets, net 2,640,921 3,022,321
Beginning balance 6,463,619 6,533,550
Other assets, net 288,397 342,966
Total assets 12,392,478 13,564,665
Current liabilities:    
Current portion of long-term debt 242 721,872
Accounts payable 167,463 204,121
Accrued expenses and other current liabilities 485,395 524,470
Total current liabilities 653,100 1,450,463
Long-term debt 3,150,476 3,177,770
Long-term liabilities 770,523 930,946
Operating Lease, Liability, Noncurrent 151,505 132,747
Total liabilities 4,725,604 5,691,926
Commitments and contingencies (see Note 15)
Stockholders' equity:    
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding 0 0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 120,646,000 and 123,426,000 shares at December 29, 2024 and December 31, 2023, respectively 120,646 123,426
Capital in excess of par value 2,097,110 2,416,793
Retained earnings 5,845,223 5,609,212
Accumulated other comprehensive loss (396,105) (276,692)
Total stockholders' equity 7,666,874 7,872,739
Total liabilities and stockholders' equity $ 12,392,478 $ 13,564,665
v3.25.0.1
Consolidated Balance Sheet Parenthetical - $ / shares
Dec. 29, 2024
Dec. 31, 2023
Balance Sheet Parenthetical [Abstract]    
Preferred stock, par value $ 1 $ 1
Preferred stock, authorized 1,000,000 1,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 1 $ 1
Common stock, authorized 300,000,000 300,000,000
Common stock, issued 120,646,000 123,426,000
Common stock, outstanding 120,646,000 123,426,000
v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock Amount [Member]
Common Stock Amount [Member]
Net Income [Member]
Common Stock Amount [Member]
Other comprehensive loss [Member]
Common Stock Amount [Member]
Dividends [Member]
Common Stock Amount [Member]
Exercise of employee stock options and related income tax benefits [Member]
Common Stock Amount [Member]
Purchases of common stock [Member]
Common Stock Amount [Member]
Issuance of common stock for employee stock purchase plans [Member]
Common Stock Amount [Member]
Issuance of common stock for long-term incentive program [Member]
Common Stock Amount [Member]
Stock compensation [Member]
Capital In Excess of Par Value [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Common stock, outstanding   126,241,000                      
Beginning Balance at Jan. 02, 2022 $ 7,141,245 $ 126,241                 $ 2,760,522 $ 4,417,174 $ (162,692)
Net income 569,179                     569,179  
Other comprehensive income (loss) (284,805)                        
Dividends 35,335                     35,335 0
Exercise of employee stock options and related income tax benefits 14,114 195                 13,919    
Issuance of common stock for employee benefit plans 4,172 31                 4,141    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 80,638 493                 80,145    
Issuance of common stock for long-term incentive program 44,561 326                 44,235    
Stock compensation 10,383 0                 10,383 0 0
Ending Balance at Jan. 01, 2023 7,382,876 $ 126,300                 2,753,055 4,951,018 (447,497)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (284,805)                        
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax (284,805)                       (284,805)
Common stock, outstanding   126,300,000 0 0 0 195,000 (493,000) 31,000 326,000 0      
Net income 693,094                     693,094  
Other comprehensive income (loss) 170,805                        
Dividends 34,900                     34,900  
Exercise of employee stock options and related income tax benefits 4,344 $ 58                 4,286    
Issuance of common stock for employee benefit plans 3,132 29                 3,103    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 392,302 3,267                 389,035    
Issuance of common stock for long-term incentive program 35,192 306                 34,886    
Stock compensation 10,498 0                 10,498 0 0
Ending Balance at Dec. 31, 2023 7,872,739 $ 123,426                 2,416,793 5,609,212 (276,692)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 79,991                        
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ 170,805                       170,805
Common stock, outstanding 123,426,000 123,426,000 0 0 0 58,000 (3,267,000) 29,000 306,000 0      
Net income $ 270,385                     270,385  
Other comprehensive income (loss) (119,413)                        
Dividends 34,374                     34,374  
Exercise of employee stock options and related income tax benefits 7,701 $ 117                 7,584    
Issuance of common stock for employee benefit plans 1,428 14                 1,414    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 369,368 3,146                 366,222    
Issuance of common stock for long-term incentive program 28,066 235                 27,831    
Stock compensation 9,710 0                 9,710 0 0
Ending Balance at Dec. 29, 2024 7,666,874 $ 120,646                 $ 2,097,110 $ 5,845,223 (396,105)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (119,413)                        
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ (119,413)                       $ (119,413)
Common stock, outstanding 120,646,000 120,646,000 0 0 0 117,000 (3,146,000) 14,000 235,000 0      
v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 1,164,452 $ 914,373 $ 470,746 $ 619,337
Operating activities:        
Net income 270,385 693,094 569,179  
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12,686 (513,591) (56,503)  
Income from continuing operations 283,071 179,503 512,676  
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:        
Restructuring Charges and Changes in Estimates 17,454 26,601 13,580  
Depreciation and amortization 427,849 431,769 427,000  
Stock-based compensation 37,809 41,410 51,518  
Pension and other post-retirement expense (income) 9,381 23,089 (23,104)  
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability (1,869) 4,168 (1,377)  
Deferred taxes (102,232) (123,664) (105,923)  
Contingencies and Non-Cash Tax Matters (8,073) 26,183 (1,488)  
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts 6,073 7,349 7,310  
Gain on disposition of businesses and assets, net 0 0 (2,887)  
Amortization of acquired inventory revaluation 0 0 45,289  
Asset Impairment Charges 22,814 0 0  
Change in fair value of investments (7,958) 33,921 15,754  
Gain (Loss) on Extinguishment of Debt 0 (3,685) (2,880)  
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax (1,059) 24,089 0  
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:        
Accounts receivable, net (15,969) (8,997) 66,093  
Inventories, net 45,086 (14,109) (48,634)  
Accounts payable (26,025) (76,426) (43,804)  
Accrued expenses and other (21,397) (291,814) (236,623)  
Net cash provided by operating activities of continuing operations 664,955 279,387 672,500  
Net cash (used in) provided by operating activities of discontinued operations (36,656) (188,115) 7,310  
Net cash provided by operating activities 628,299 91,272 679,810  
Investing activities:        
Capital expenditures (86,648) (81,368) (85,632)  
Purchases of investments and notes receivables (6,587) (6,300) (47,181)  
Payments to Acquire Marketable Securities 0 (1,221,609) 0  
Proceeds from Sale and Maturity of Marketable Securities 710,000 550,000 0  
Proceeds from investments and notes receivables 2,500 0 8,890  
Proceeds from Divestiture of Businesses 0 153 14,505  
Cash paid for acquisitions, net of cash acquired 0 (2,086) (7,518)  
Net cash provided by (used in) investing activities of continuing operations 619,265 (761,210) (116,936)  
Net cash provided by (used in) investing activities of discontinued operations 156,897 2,074,734 (15,915)  
Net cash provided by (used in) investing activities 776,162 1,313,524 (132,851)  
Financing activities:        
Payments on revolving credit facility 0 0    
Repayments of Lines of Credit and Term Loan     (740,000)  
Proceeds from Long-term Lines of Credit 0 0 240,000  
Payments of Senior Debt (711,479) (523,808) (57,876)  
Payments of debt financing and equity issuance costs 0 (15) 0  
Proceeds from (Repayments of) Other Debt (11,593) 6,323 (1,292)  
Settlement of cash flow hedges 0 0 (762)  
Payments for acquisition-related contingent consideration (8,832) (10,117) (5)  
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 7,701 4,344 14,114  
Purchases of common stock (369,578) (388,882) (80,638)  
Dividends paid (34,454) (34,966) (35,344)  
Net cash (used in) provided by financing activities (1,128,235) (947,121) (661,803)  
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (26,147) (14,048) (33,747)  
Net increase (decrease) in cash, cash equivalents and restricted cash 250,079 443,627 (148,591)  
Cash and cash equivalents at beginning of year 913,163 454,358    
Restricted Cash, Current 1,056 1,210 1,040  
Restricted Cash, Noncurrent 0 0 349  
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents 0 0 14,999  
Cash and cash equivalents at end of year 1,163,396 913,163 454,358  
Supplemental disclosures of cash flow information        
Interest Paid, Excluding Capitalized Interest, Operating Activities 91,092 94,008 97,934  
Income taxes 154,876 359,800 323,077  
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]        
Consideration receivable from sale of Business $ 0 $ 241,353 $ 0  
v3.25.0.1
Interest and Other Expense (Income), Net
 12 Months Ended
Dec. 29, 2024
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net Interest and Other Expense, Net
Interest and other expense, net, consisted of the following for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Interest income$(73,190)$(72,131)$(3,589)
Interest expense96,278 98,813 103,955 
Change in fair value of investments(7,958)33,921 15,754 
Other components of net periodic pension cost (credit)8,508 19,006 (33,158)
Foreign exchange losses and other expense, net6,977 37,977 7,900 
Total interest and other expense, net$30,615 $117,586 $90,862 
v3.25.0.1
Interest and Other Expense (Income), Net
 12 Months Ended
Dec. 29, 2024
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net
Interest and other expense, net, consisted of the following for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Interest income$(73,190)$(72,131)$(3,589)
Interest expense96,278 98,813 103,955 
Change in fair value of investments(7,958)33,921 15,754 
Other components of net periodic pension cost (credit)8,508 19,006 (33,158)
Foreign exchange losses and other expense, net6,977 37,977 7,900 
Total interest and other expense, net$30,615 $117,586 $90,862 
v3.25.0.1
Interest and Other Expense (Income), Net - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Interest income $ (73,190) $ (72,131) $ (3,589)
Change in fair value of investments (7,958) 33,921 15,754
Other components of net periodic pension cost (credit) 8,508 19,006 (33,158)
Foreign exchange losses and other expense (income), net 6,977 37,977 7,900
Total interest and other expense, net 30,615 117,586 90,862
Interest Expense, Nonoperating $ 96,278 $ 98,813 $ 103,955
v3.25.0.1
Nature of Operations and Accounting Policies
 12 Months Ended
Dec. 29, 2024
Accounting Policies [Abstract]  
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies
Nature of Operations:    Revvity, Inc. (the “Company”) is a leading provider of health sciences solutions, technologies, expertise and services that deliver complete workflow from discovery to development, and diagnosis to cure. The Company has two operating segments: Life Sciences and Diagnostics. The Company’s Life Sciences segment focuses on service and innovating for customers spanning the life sciences market. The Company’s Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health, emerging market diagnostics and applied genomics.
The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In March 2023, the Company completed the sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”). The Business is reported for all periods as discontinued operations in the Company’s consolidated financial statements.
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a
52/53-week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 29, 2024 (“fiscal year 2024”), December 31, 2023 (“fiscal year 2023”) and January 1, 2023 (“fiscal year 2022”) included 52 weeks. The fiscal year ending December 28, 2025 (“fiscal year 2025”) will include 52 weeks.
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers.
Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue.
The Company reports shipping and handling revenue in revenue, to the extent it is billed to customers, and the associated costs in cost of product revenue.
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense.
The Company is subject to the Global Intangible Low Taxed Income (“GILTI”) tax in the U.S. The Company elected to treat taxes on future GILTI inclusions in U.S. taxable income as a current period expense when incurred.
The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income.
Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings - 10 to 40 years; leasehold improvements - estimated useful life or remaining term of lease, whichever is shorter; and machinery, equipment and capitalized internal-use software - 3 to 10 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. The Company capitalizes certain qualified costs incurred in connection with the development of internal-use software. The Company evaluates the costs incurred during the application development stage of internal use software to determine whether the costs meet the criteria for capitalization. Costs related to preliminary project activities and post implementation activities are expensed as incurred.
Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company’s fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income (“AOCI”), a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net.
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses. Measurement period adjustments are made in the period in which the amounts are determined, and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets:  The Company’s intangible assets consist of (i) goodwill, which is not being amortized; and (ii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. During the fourth quarter of fiscal year 2024, the Company voluntarily changed its annual goodwill impairment testing date from the later of January 1 or the first day of each fiscal year to the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. The Company changed the measurement date to more closely align the annual impairment testing date with the most current information from the budgeting and strategic planning process. The Company believes the change in goodwill impairment testing date does not represent a material change to the Company’s method of applying an accounting principle in light of the Company’s internal controls and requirements to assess goodwill impairment upon certain triggering events. This change was applied prospectively and
therefore, the Company performed its annual impairment testing for its reporting units for fiscal year 2024 as of January 1, 2024 and November 1, 2024. The Company concluded that there was no goodwill impairment in the periods presented.
Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values.
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model or the quoted price of the Company’s stock on the grant date. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation.
 Marketable Securities and Investments:  Investments in debt securities that are classified as available for sale are recorded at fair value with unrealized gains and losses included in AOCI until realized. Investments in debt securities that are classified as held-to-maturity are recorded at amortized cost. Investments in equity securities are recorded at fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair values are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred.
Cash and Cash Equivalents: The Company considers all highly liquid, unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
 Research and Development: Research and development costs are expensed as incurred.
Restructuring and Other Costs: Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. The Company recorded restructuring charges, included in selling, general and administrative expenses in the consolidated statements of operations, of $17.5 million, $26.6 million and $13.6 million primarily associated with workforce reductions during fiscal years 2024, 2023 and 2022, respectively. The Company expects severance payments will be substantially completed during fiscal year 2025.
Comprehensive Income:  Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded
as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements.
The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 will require public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The guidance is required to be applied on a prospective basis; retrospective application is permitted. The guidance is
effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.
In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 amends Accounting Standards Codification 280, Segment Reporting (“ASC 280”) to require public entities to disclose significant segment expenses and other segment items that are regularly provided to the chief operating decision maker (“CODM”) and included in each reported measure of a reportable segment’s profit or loss, on an annual and interim basis, and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 permits entities to report multiple measures of a reportable segment’s profit or loss if the CODM uses those measures to allocate resources and assess performance. The Company adopted the guidance in fiscal year 2024 and has included the additional disclosures related to the reportable segments in Note 21, Industry Segment and Geographic Area Information.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 will require public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The guidance is required to be applied on a prospective basis; retrospective application is permitted. The guidance is
effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.
In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 amends Accounting Standards Codification 280, Segment Reporting (“ASC 280”) to require public entities to disclose significant segment expenses and other segment items that are regularly provided to the chief operating decision maker (“CODM”) and included in each reported measure of a reportable segment’s profit or loss, on an annual and interim basis, and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 permits entities to report multiple measures of a reportable segment’s profit or loss if the CODM uses those measures to allocate resources and assess performance. The Company adopted the guidance in fiscal year 2024 and has included the additional disclosures related to the reportable segments in Note 21, Industry Segment and Geographic Area Information.
v3.25.0.1
Revenue from Contract with Customer
 12 Months Ended
Dec. 29, 2024
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block] Revenue
For arrangements with multiple performance obligations, the Company accounts for individual products and services separately if they are distinct - i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated to each performance obligation in an arrangement based on relative stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis.
The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty).
In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year.
Nature of goods and services
The Life Sciences segment principally generates revenue from sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services in the life sciences market. The Diagnostics segment principally generates revenue from sales of instruments, solutions, consumables, reagents, and services in the diagnostics market. The typical length of a contract for service is 12 to 36 months.
The revenue generated from the sale of instruments (inclusive of consumables), reagents, and certain software is recognized at a point in time. The Company recognizes revenue in these arrangements at the point in time when control of the products has been transferred to customers, which is typically at delivery. Certain of the Company’s products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days.
The revenue generated from the sale of licenses for software as a service, cloud services, subscriptions, and laboratory services and training is recognized over time. Software as a service, subscriptions and cloud services, are generally recognized ratably over the contract period. The Company sells its software subscriptions and cloud services with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software commencing when the service is made available to the customer. For maintenance and consulting services, revenue is recognized over the period in which the services are provided. Revenue for laboratory services is recognized over the contract period or when the service is billable, based on an input method that is based on time and materials.
Product revenue is recognized at a point in time and service revenue is generally recognized over time.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines.
Reportable Segments
For the fiscal year ended
December 29, 2024December 31, 2023January 1, 2023
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$659,444 $563,642 $1,223,086 $671,738 $543,875 $1,215,613 $683,170 $979,473 $1,662,643 
Europe283,256 459,358 742,614 308,567 438,457 747,024 297,468 534,343 831,811 
Asia311,445 477,881 789,326 312,035 475,899 787,934 312,271 505,097 817,368 
$1,254,145 $1,500,881 $2,755,026 $1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 
Major goods/service lines
Life Sciences reagents$719,268 $— $719,268 $732,789 $— $732,789 $691,344 $— $691,344 
Life Sciences instruments334,078 — 334,078 381,262 — 381,262 405,554 — 405,554 
Life Sciences software200,799 — 200,799 178,289 — 178,289 196,011 — 196,011 
Reproductive health— 523,931 523,931 — 501,302 501,302 — 516,574 516,574 
Applied genomics— 204,760 204,760 — 228,443 228,443 — 393,602 393,602 
Immunodiagnostics— 772,190 772,190 — 728,486 728,486 — 1,108,737 1,108,737 
$1,254,145 $1,500,881 $2,755,026 $1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 

Major Customer Concentration
No single customer comprises more than 10% of net revenues during the fiscal years 2024 and 2023. Revenues from one customer in the Company’s Diagnostics segment represented approximately $330.7 million, or 10%, of the Company’s total revenue during the fiscal year 2022.
Contract Balances
Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. The unbilled receivables are classified as either current in “Accounts receivable, net” or as long-term in “Other assets, net” in the consolidated balance sheets. Unbilled receivables totaled $80.6 million and $75.8 million at December 29, 2024 and December 31, 2023, respectively, primarily related to the Life Sciences software business. The Company has no material contract assets as of December 29, 2024 and December 31, 2023.
Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Long-term liabilities” in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. Substantially all of the deferred revenue is expected to be recognized in revenue within 12 months of the balance sheet date, and has been classified within accrued expenses and other current liabilities. The deferred revenue balance is primarily related to our software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $212.8 million and $209.7 million at December 29, 2024 and December 31, 2023, respectively. The Company also has customer deposits received in advance of the transfer of control totaling $19.5 million and $22.1 million at December 29, 2024 and December 31, 2023, respectively. The Company expects that these customer deposits will be recognized in revenue within 3 months of the balance sheet date.
Transaction price allocated to the remaining performance obligations
The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related
to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
v3.25.0.1
Discontinued Operations
 12 Months Ended
Dec. 29, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations Discontinued Operations
On March 13, 2023, the Company completed the sale (the “Closing”) of the Business to PerkinElmer Topco, L.P. (formerly known as Polaris Purchaser, L.P.) (the “Purchaser”), a Delaware limited partnership owned by funds managed by affiliates of New Mountain Capital L.L.C. (the “Sponsor”), for an aggregate purchase price of up to $2.45 billion. The Company received approximately $2.27 billion in cash proceeds before transaction costs. At the Closing, the Company was entitled to an additional $75.0 million in proceeds payable in installments to commence upon the Company’s ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the Purchaser (the “Brand Fee”). The discounted value of the $75.0 million was measured as $65.2 million and was included in the proceeds at Closing. During the fiscal year 2024, the Company received $18.8 million of the Brand Fee. The Company expects to receive the remaining balance of the Brand Fee in installments in 2025. In addition, the Company is entitled to additional consideration of up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive on a sale or other capital events related to the Business. The fair value of this element of consideration was determined to be $15.9 million and was included in the proceeds at Closing. During fiscal year 2024, the Company received approximately $138.5 million of cash from the Purchaser and recognized a loss of $19.8 million primarily related to post-closing adjustments.
In connection and concurrent with the Closing, the Company has also entered into a Transition Services Agreement (“TSA”) with the Purchaser for a period of up to 24 months from the Closing, with the options to renew. The costs and amounts of reimbursements related to the TSA and other commercial transactions between the parties were not significant in fiscal years 2024 and 2023 and the amounts in future periods are not expected to be significant.
The Business had been reported in the Company’s Discovery & Analytical Solutions segment, which is now referred to as the Life Sciences segment. The sale of the Business represented a strategic shift that had a major effect on the Company's operations and financial statements. Accordingly, the Business is reported for all periods as discontinued operations in the Company’s consolidated financial statements. The following table summarizes the results of discontinued operations which are presented as income from discontinued operations in the Company’s consolidated statements of operations:
 December 29, 2024December 31, 2023January 1, 2023
 (In thousands)
Revenue$— $176,324 $1,298,376 
Cost of revenue— 125,219 859,330 
Selling, general and administrative expenses— 78,613 306,032 
Research and development expenses— 10,434 64,605 
Operating (loss) income— (37,942)68,409 
Other (loss) income:
(Loss) gain on sale(25,448)811,472 — 
Other (expense) income, net— (49)5,195 
Total other (loss) income(25,448)811,423 5,195 
(Loss) income from discontinued operations before income taxes(25,448)773,481 73,604 
(Benefit from) provision for income tax(12,762)259,890 17,101 
(Loss) income from discontinued operations$(12,686)$513,591 $56,503 
The following operating and investing items from discontinued operations were as follows for the fiscal years ended:
December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Depreciation
$— $— $8,011 
Amortization
— — 16,984 
Capital expenditures— 1,292 10,670 
v3.25.0.1
Income Taxes
 12 Months Ended
Dec. 29, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of income from continuing operations before income taxes were as follows for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
U.S.$134,177 $51,314 $326,438 
Non-U.S.181,949 131,662 325,399 
Total$316,126 $182,976 $651,837 
The components of the provision for income taxes on continuing operations were as follows:
 
Current
Expense		Deferred 
Expense
(Benefit)		Total
(In thousands)
Fiscal year ended December 29, 2024
Federal$42,708 $(34,407)$8,301 
State17,040 (10,962)6,078 
Non-U.S.75,539 (56,863)18,676 
Total$135,287 $(102,232)$33,055 
Fiscal year ended December 31, 2023
Federal$39,800 $(60,845)$(21,045)
State9,183 (19,619)(10,436)
Non-U.S.78,154 (43,200)34,954 
Total$127,137 $(123,664)$3,473 
Fiscal year ended January 1, 2023
Federal$115,436 $(45,246)$70,190 
State27,757 (16,139)11,618 
Non-U.S.101,891 (44,538)57,353 
Total$245,084 $(105,923)$139,161 
The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: 
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Continuing operations$33,055 $3,473 $139,161 
Discontinued operations(12,762)259,890 17,101 
Total$20,293 $263,363 $156,262 
 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Tax at statutory rate$66,386 $38,346 $136,886 
Non-U.S. rate differential, net(13,332)(18,479)(5,221)
U.S. taxation of multinational operations(28,879)(4,594)22,102 
State income taxes, net2,174 (265)7,820 
Impact of rate changes— (12,795)— 
Prior year tax matters(9,389)3,971 (10,160)
Effect of stock compensation2,960 2,225 845 
General business tax credits(17,634)(4,718)(7,132)
Transfer pricing matters(2,391)(6,725)— 
Change in valuation allowance29,781 6,772 4,964 
Effect of foreign repatriations5,329 (4,737)(4,940)
Other, net(1,950)4,472 (6,003)
Total$33,055 $3,473 $139,161 
The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The Company has recognized the change in tax positions in prior periods through both continuing and discontinuing operations.
The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended:
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Unrecognized tax benefits, beginning of year$129,056 $57,948 $61,658 
Gross increases—tax positions in prior periods29,623 64,697 1,489 
Gross decreases—tax positions in prior periods— — (2,519)
Gross increases—current-period tax positions— 14,969 7,187 
Lapse of statute of limitations(7,251)(10,830)(8,625)
Foreign currency translation adjustments(1,643)2,272 (1,242)
Unrecognized tax benefits, end of year$149,785 $129,056 $57,948 
The Company classifies interest and penalties as a component of income tax expense. At December 29, 2024 and December 31, 2023, the Company had accrued interest and penalties of $5.1 million and $6.3 million, respectively. During fiscal years 2024, 2023 and 2022, the Company recognized a net benefit of $1.2 million, $1.1 million and $0.5 million, respectively, for interest and penalties in its total tax provision. At December 29, 2024, substantially all of the unrecognized tax benefits, if recognized, would affect the effective tax rate.
The Company believes that it is reasonably possible that approximately $76.1 million of its uncertain tax positions at December 29, 2024, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Luxembourg, The Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities were as follows: 
December 29,
2024		December 31,
2023
(In thousands)
Deferred tax assets:
Inventory$11,548 $12,934 
Reserves and accruals70,544 63,711 
Accrued compensation23,637 18,339 
Net operating loss and credit carryforwards176,504 133,919 
Accrued pension12,773 11,089 
Restructuring reserve1,369 1,588 
Deferred revenue18,388 17,539 
Capitalized research and development expenses69,208 47,188 
Operating lease liabilities33,468 29,319 
Unrealized foreign exchange loss
2,612 12,502 
All other, net775 1,610 
Total deferred tax assets420,826 349,738 
Deferred tax liabilities:
Postretirement health benefits(5,139)(4,452)
Depreciation and amortization(688,771)(784,925)
Operating lease right-of-use assets(30,881)(26,301)
Prepaid expenses(375)(349)
Deferred tax liability on foreign earnings(19,662)(17,587)
Total deferred tax liabilities(744,828)(833,614)
Valuation allowance(126,488)(84,626)
Net deferred tax liabilities$(450,490)$(568,502)

The components of net deferred tax liabilities were recognized in the consolidated balance sheets as follows:
December 29,
2024		December 31,
2023
(In thousands)
Other assets, net$5,613 $8,158 
Deferred taxes and other long-term liabilities(456,103)(576,660)
Total$(450,490)$(568,502)

At December 29, 2024, the Company had U.S. federal net operating loss carryforwards of $104.9 million, state net operating loss carryforwards of $6.2 million, foreign net operating loss carryforwards of $549.8 million, state tax credit carryforwards of $11.8 million and foreign tax credit carryforwards of $24.7 million. Certain net operating loss carryforwards and state credit carryforwards do not expire, while other losses begin to expire in 2025.
Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The increase in the valuation allowance of $29.8 million in fiscal year 2024 was primarily due to generation of foreign tax credit carryforwards for which a benefit is not expected to be realized in future periods.
The Company records the applicable taxes associated with the future remittance of undistributed foreign earnings previously taxed at the U.S. federal level and/or that would be claimed for a dividend received deduction if repatriated. For the remaining other undistributed foreign earnings and outside basis differences we continue to be indefinitely reinvested and have
not provided any taxes for these amounts, and it is not practicable to estimate the amount of deferred tax liability that would be incurred.
v3.25.0.1
Earnings Per Share
 12 Months Ended
Dec. 29, 2024
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:

December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Number of common shares—basic122,756 124,704 126,155 
Effect of dilutive securities:
Stock options57 108 249 
Restricted stock awards9 — 22 
Number of common shares—diluted122,822 124,812 126,426 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact951 1,089 611 
Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive securities also include restricted stock awards with average unrecognized compensation cost in excess of the average fair market value of the common stock for the related period. Antidilutive options and restricted stock awards were excluded from the calculation of diluted net income per share and could become dilutive in the future.
v3.25.0.1
Accounts Receivable, Net
 12 Months Ended
Dec. 29, 2024
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]  
Accounts Receivable, Net Accounts Receivable, Net
Accounts receivable, net consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Accounts receivable, net$632,400 $632,811 
Long-term accounts receivable, net, included in Other assets, net28,163 29,593 
Total accounts receivable, net$660,563 $662,404 
Reserves for credit losses consisted of the following:
Balance at Beginning of YearProvisionsCharges/
Write-offs
Other(1)
Balance at End
of Year
  (In thousands)
Year ended January 1, 2023$38,254 $9,857 $(9,672)$(896)$37,543 
Year ended December 31, 202337,543 9,067 (3,559)329 43,380 
Year ended December 29, 202443,380 9,715 (4,487)(636)47,972 
(1) Other amounts primarily relate to the impact of acquisitions, discontinued operations and foreign exchange movements.
v3.25.0.1
Inventories, Net
 12 Months Ended
Dec. 29, 2024
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
Inventories, net consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Raw materials$174,502 $197,268 
Work in progress65,191 69,176 
Finished goods127,894 161,618 
Total inventories, net$367,587 $428,062 
v3.25.0.1
Property, Plant and Equipment, Net
 12 Months Ended
Dec. 29, 2024
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment, Net Property, Plant and Equipment, Net
Property, plant and equipment consisted of the following:
December 29,
2024		December 31,
2023
(In thousands)
At cost:
Land$29,521 $29,635 
Building and leasehold improvements364,556 358,380 
Machinery, equipment and capitalized internal-use software587,807 595,124 
Total property, plant and equipment981,884 983,139 
Accumulated depreciation(499,667)(473,485)
Total property, plant and equipment, net$482,217 $509,654 
Depreciation expense on property, plant and equipment for the fiscal years ended December 29, 2024, December 31, 2023 and January 1, 2023 was $68.5 million, $66.7 million and $56.4 million, respectively. During fiscal year 2024, the Company recognized an asset impairment amounting to $22.8 million related to capitalized internal-use software in the Diagnostics segment, which is included in Selling, general and administrative expenses in the consolidated statements of operations.
v3.25.0.1
Marketable Securities and Investments
 12 Months Ended
Dec. 29, 2024
Marketable Securities [Abstract]  
Marketable Securities and Investments Marketable Securities and Investments
 Investments consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Marketable securities - held to maturity (current)$— $689,916 
Marketable securities - available for sale27,413 13,913 
Equity investments56,170 57,206 
Notes receivables and other investments12,337 12,280 
$95,920 $773,315 

Marketable securities - held to maturity. The Company’s investments in U.S. treasury securities were classified as held-to-maturity and measured at amortized cost. The Company has no outstanding investments in U.S. treasury securities as of December 29, 2024. All the outstanding investments in U.S. treasury securities as of December 31, 2023 had a contractual maturity of less than one year and have been classified as current in the consolidated balance sheet to match the maturities of the long-term debt that was retired concurrently with the maturity of the marketable securities.
Marketable securities - available for sale. Marketable securities, which are included in Other assets, net, are accounted for as available for sale and include equity and fixed-income securities. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income (loss) in the consolidated statements of stockholders’ equity, was not material. The proceeds from the sales of securities and the related gains and losses are not material for any period presented.
Equity investments. The Company has equity interests in privately-held entities over which the Company neither has significant influence nor control. Equity investments, which are included in Other assets, net, as of December 29, 2024 and December 31, 2023 consisted of the following:
December 29,
2024		December 31,
2023
(In thousands)
Equity investments, carried at cost minus impairment, if any$46,460 $47,260 
Equity investments, carried at fair value9,710 9,946 
$56,170 $57,206 
The amount of upward adjustments during the periods presented were not material. The cumulative amount of upward adjustments as of each of December 29, 2024 and December 31, 2023 was $31.3 million. The amount of impairment during fiscal year 2024 was $2.1 million. The cumulative amount of impairments and downward adjustments as of December 29, 2024 and December 31, 2023 was $7.1 million and $5.0 million, respectively.
Notes receivables and other investments. Notes receivables and other investments, which are included in Other assets, net, are carried at cost less allowance for credit losses. The amortized cost of these investments are not materially different than the fair value. Notes receivables and other investments with a notional amount and carrying value of $0.3 million are due within one to five years. Notes receivables and other investments with a notional amount and carrying value of $12.0 million are convertible into equity securities or are due and payable upon an event of default (as defined in the applicable agreement). The credit losses, included in Interest and other expense, net, in the consolidated statements of operations, during fiscal years 2024, 2023 and 2022 were $1.8 million, $34.5 million and $—, respectively.
v3.25.0.1
Goodwill and Intangible Assets, Net
 12 Months Ended
Dec. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
The changes in the carrying amount of goodwill for fiscal years 2024 and 2023 are as follows:
Life SciencesDiagnosticsConsolidated
(In thousands)
Balance at January 1, 2023$4,551,575 $1,930,193 $6,481,768 
Foreign currency translation36,363 15,419 51,782 
Balance at December 31, 20234,587,938 1,945,612 6,533,550 
Foreign currency translation(46,471)(23,460)(69,931)
Balance at December 29, 2024$4,541,467 $1,922,152 $6,463,619 

Identifiable intangible asset balances at December 29, 2024 and December 31, 2023 were as follows:
December 29,
2024		December 31,
2023
(In thousands)
Patents$27,808 $27,811 
Less: Accumulated amortization(26,293)(26,072)
Net patents1,515 1,739 
Trade names and trademarks142,588 145,542 
Less: Accumulated amortization(87,824)(73,781)
Net trade names and trademarks54,764 71,761 
Licenses27,164 27,018 
Less: Accumulated amortization(17,855)(16,551)
Net licenses9,309 10,467 
Core technology1,561,831 1,582,458 
Less: Accumulated amortization(735,532)(607,814)
Net core technology826,299 974,644 
Customer relationships2,807,909 2,842,531 
Less: Accumulated amortization(1,058,875)(878,821)
Net customer relationships1,749,034 1,963,710 
Net amortizable intangible assets$2,640,921 $3,022,321 
Total amortization expense related to amortizable intangible assets was $359.4 million in fiscal year 2024, $365.1 million in fiscal year 2023 and $370.6 million in fiscal year 2022. Estimated amortization expense related to amortizable intangible assets for each of the next five years is $331.5 million in fiscal year 2025, $325.6 million in fiscal year 2026, $298.8 million in fiscal year 2027, $273.4 million in fiscal year 2028, and $244.9 million in fiscal year 2029.
v3.25.0.1
Debt
 12 Months Ended
Dec. 29, 2024
Debt Disclosure [Abstract]  
Debt Debt
 The Company’s debt consisted of the following:
December 29, 2024
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,208)$(1,208)
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)521,700 (834)(780)520,086 
1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”)
500,000 (200)(2,408)497,392 
3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”)850,000 (1,448)(4,010)844,542 
2.55% Senior Unsecured Notes due in March 2031 (“March 2031 Notes”)400,000 (88)(2,294)397,618 
2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”)
500,000 (1,065)(3,059)495,876 
3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”)400,000 (4)(4,059)395,937 
Other Debt Facilities, non-current233 — — 233 
Total Long-Term Debt3,171,933 (3,639)(17,818)3,150,476 
Current Portion of Long-Term Debt:
Other Debt Facilities, current242 — — 242 
Total Current Portion of Long-Term Debt242 — — 242 
Total Debt$3,172,175 $(3,639)$(17,818)$3,150,718 
December 31, 2023
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,966)$(1,966)
2026 Notes553,450 (1,438)(1,279)550,733 
2028 Notes500,000 (250)(3,024)496,726 
2029 Notes850,000 (1,727)(4,781)843,492 
March 2031 Notes400,000 (101)(2,638)397,261 
September 2031 Notes500,000 (1,210)(3,568)495,222 
2051 Notes400,000 (4)(4,158)395,838 
Other Debt Facilities, non-current464 — — 464 
Total Long-Term Debt3,203,914 (4,730)(21,414)3,177,770 
Current Portion of Long-Term Debt:
0.850% Senior Unsecured Notes due in 2024 (“2024 Notes”)
711,479 (118)(1,301)710,060 
Other Debt Facilities, current11,812 — — 11,812 
Total Current Portion of Long-Term Debt723,291 (118)(1,301)721,872 
Total Debt$3,927,205 $(4,848)$(22,715)$3,899,642 
Senior Unsecured Revolving Credit Facility. On August 24, 2021, the Company entered into a senior unsecured revolving credit facility (“2021 Senior Unsecured Revolving Credit Facility”) with a five-year term and a borrowing capacity of $1.5 billion available through August 24, 2026. As of December 29, 2024, undrawn letters of credit in the aggregate amount of $4.2 million were treated as issued and outstanding when calculating the borrowing availability under the facility. As of December 29, 2024, the Company had $1.5 billion available for additional borrowing under the facility. Borrowings bore interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as described in the credit agreement), or (b) the eurocurrency rate (a publicly published rate), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate was the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) the Eurocurrency Rate plus 1.00%. The credit agreement for the facility contained customary affirmative, negative and financial covenants and events of default. The financial covenants included a debt-to-capitalization ratio that remained applicable for so long as the Company’s debt was rated as investment grade. In the event that the Company’s debt was not rated as investment grade, the debt-to-capitalization ratio covenant was replaced with leverage ratio and interest coverage ratio covenants.
On January 7, 2025, the 2021 Senior Unsecured Revolving Credit Facility was cancelled and replaced with a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through January 7, 2030. Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as described in the credit agreement), or (b) the Term Secured Overnight Financing Rate (“Term SOFR”) (as described in the credit agreement), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate is the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) Term SOFR plus 1.00%. The credit agreement for the new facility contains customary affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capitalization ratio that remains applicable for so long as the Company’s debt is rated as investment grade. In the event that the Company’s debt is not rated as investment grade, the debt-to-capitalization ratio covenant is replaced with leverage ratio and interest coverage ratio covenants.
During fiscal year 2024, the Company paid in full $711.5 million of outstanding 2024 Notes that became due in September 2024. During fiscal year 2024, the Company received proceeds of $710.0 million upon the maturity of all its outstanding U.S. Treasury securities and utilized those proceeds to partially repay the outstanding 2024 Notes.
The following table summarizes the maturities of the Company’s indebtedness as of December 29, 2024: 
(In thousands)
2025$242 
2026521,781 
202781 
2028500,071 
2029850,000 
2030 and thereafter1,300,000 
Total debt payments$3,172,175 
v3.25.0.1
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 29, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Payroll and incentives$74,984 $50,526 
Employee benefits44,183 43,279 
Deferred revenue140,212 135,555 
Federal, non-U.S. and state income taxes74,403 88,159 
Operating lease liabilities
23,582 32,906 
Other accrued operating expenses128,031 174,045 
Total accrued expenses and other current liabilities$485,395 $524,470 
v3.25.0.1
Employee Benefit Plans
 12 Months Ended
Dec. 29, 2024
Retirement Benefits [Abstract]  
Employee Benefit Plans Employee Benefit Plans
 Savings Plan:    The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $13.3 million in fiscal year 2024, $15.0 million in fiscal year 2023, and $20.0 million in fiscal year 2022.
Pension Plans:    The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan is closed to new hires and plan benefits have been frozen. The plans provide benefits that are based on an employee’s years of service and compensation near retirement.
In December 2024, the Company entered into an annuity purchase agreement to irrevocably transfer a portion of the U.S. pension benefit obligation to a third-party insurance company. The annuity purchase price was $96.3 million and was funded from U.S. pension plan assets. The resulting settlement of the U.S. pension plan was not material and included in the actuarial gains and losses recognized during the fiscal year 2024.
In January 2025, the Company executed a sale of its United Kingdom (“UK”) pension plan to a third party as part of a multi-year buy-out plan. The resulting settlement of the UK pension plan was not material.
 Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended:
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Service and administrative costs$5,017 $5,736 $6,331 
Interest cost17,008 19,585 10,751 
Expected return on plan assets(12,899)(14,600)(22,056)
Actuarial losses (gains)1,188 9,341 (23,706)
Net periodic pension cost (credit)$10,314 $20,062 $(28,680)
The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company’s control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Actuarial gains and losses, including other components of periodic pension cost, are recognized in the line item “Interest and other expense, net” in the consolidated statements of operations.
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2024 and December 31, 2023.
 December 29, 2024December 31, 2023
Non-U.S.U.S.Non-U.S.U.S.
(In thousands)
Actuarial present value of benefit obligations:
Accumulated benefit obligations$212,120 $90,293 $227,174 $208,505 
Change in benefit obligations:
Projected benefit obligations at beginning of year$227,579 $208,505 $207,955 $231,492 
Service and administrative costs3,442 1,575 4,011 1,725 
Interest cost7,966 9,042 8,843 10,742 
Benefits paid and plan expenses(14,770)(20,986)(15,061)(39,895)
Plan settlements— (96,270)— — 
Actuarial losses (gains)(2,950)(11,573)12,871 4,441 
Effect of exchange rate changes(9,147)— 8,960 — 
Projected benefit obligations at end of year$212,120 $90,293 $227,579 $208,505 
Change in plan assets:
Fair value of plan assets at beginning of year$112,305 $202,331 $106,741 $216,748 
Actual return on plan assets(9,513)6,702 7,094 15,478 
Benefits paid and plan expenses(14,770)(20,986)(15,061)(39,895)
Employer’s contributions7,066 — 7,606 10,000 
Plan settlements— (96,270)— — 
Effect of exchange rate changes(1,588)— 5,925 — 
Fair value of plan assets at end of year$93,500 $91,777 $112,305 $202,331 
Net liabilities recognized in the consolidated balance sheets$(118,620)$1,484 $(115,274)$(6,174)
Net amounts recognized in the consolidated balance sheets consist of:
Other assets$7,552 $1,484 $19,540 $— 
Current liabilities(7,099)— (6,899)— 
Long-term liabilities(119,073)— (127,915)(6,174)
Net liabilities recognized in the consolidated balance sheets$(118,620)$1,484 $(115,274)$(6,174)
Actuarial assumptions as of the year-end measurement date:
Discount rate4.19 %5.71 %3.69 %4.54 %
Rate of compensation increase3.19 %None3.19 %None
Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
December 29, 2024December 31, 2023January 1, 2023
Non-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Discount rate3.69 %4.54 %4.12 %4.84 %1.41 %2.44 %
Rate of compensation increase3.19 %None3.16 %None2.78 %None
Expected rate of return on assets3.78 %4.60 %3.92 %4.80 %1.11 %7.25 %
 
The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate.
The Company’s discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans.
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
December 29,
2024		December 31,
2023
(In thousands)
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
Projected benefit obligations$126,172 $134,814 
Fair value of plan assets— — 
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations$126,172 $134,409 
Fair value of plan assets— — 
 Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 29, 2024 and December 31, 2023, and target asset allocations for fiscal year 2025 are as follows:
 Target AllocationPercentage of Plan Assets at
December 28, 2025December 29, 2024December 31, 2023
Asset CategoryNon-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Equity securities0-5%0-10%— %5 %— %6 %
Debt securities0-5%90-100%— %95 %— %94 %
Other95-100%0-10%100%— %100%— %
Total100 %100 %100 %100 %100 %100 %
The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments.
The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in mutual funds with holdings in large-cap and mid-cap companies located in the United States and abroad. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds, venture capital funds and foreign liability driven investments that follow several different strategies.
The fair value of the Company’s pension plan assets as of December 29, 2024 and December 31, 2023 by asset category, classified in the three levels of inputs described in Note 19, Fair Value Measurements, are as follows:
 
 Fair Value Measurements at December 29, 2024 Using:
Total Carrying
Value at
December 29, 2024		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash and cash equivalents$7,555 $7,555 $— $— 
Equity securities:
U.S. large-cap3,049 3,049 — — 
International large-cap value887 887 — — 
Emerging markets growth403 403 — — 
Fixed income securities:
Corporate and U.S. debt instruments83,267 25,905 57,362 — 
Short-term corporate bonds1,630 — 1,630 — 
Other types of investments:
Foreign liability driven instrument88,486 — — 88,486 
Total assets measured at fair value$185,277 $37,799 $58,992 $88,486 
 Fair Value Measurements at December 31, 2023 Using:
Total Carrying
Value at
December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash$14,223 $14,223 $— $— 
Equity Securities:
U.S. large-cap7,011 7,011 — — 
International large-cap value2,350 2,350 — — 
Emerging markets growth1,068 1,068 — — 
Fixed income securities:
Corporate and U.S. debt instruments189,318 65,228 124,090 — 
Corporate bonds— — — — 
Other types of investments:
Foreign liability driven instrument100,666 — — 100,666 
Total assets measured at fair value$314,636 $89,880 $124,090 $100,666 

Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 29, 2024 compared to December 31, 2023. The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above.

Equity Securities: Mutual funds held by the Master Trust are open‑ended mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Master Trust are deemed to be actively traded. These are categorized as Level 1 assets.

Fixed Income Securities: Fixed income U.S. government bonds are valued at quoted market prices and are categorized as Level 1 assets.
Fixed income corporate bond exchange traded funds or individual fixed income corporate bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing
methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used.
Other Types of Investments:   In September 2021, the Company’s UK pension plan executed a buy-in contract with Phoenix Life LTD (“Phoenix”), under which the Company made an upfront payment to Phoenix in exchange for Phoenix agreeing to make the benefit payments under the Company’s UK pension plan due to specified participants and their beneficiaries, thus transferring most of the investment and longevity risk associated with the covered participants and beneficiaries from the Company to Phoenix. This buy-in contract can be considered a liability-driven investment (“LDI”) solution that hedges not only the investment risk but also the longevity risk under the Company’s UK pension plan. Like other LDI solutions, it does not eliminate ongoing administrative costs. These are categorized as Level 3 assets.
The Company’s policy is to recognize significant transfers between levels at the actual date of the event.
A reconciliation of the beginning and ending Level 3 investments is as follows:
 
(In thousands)
Balance at January 1, 2023$95,062 
Pension benefits paid(6,051)
Foreign exchange losses5,957 
Return on plan assets5,698 
Balance at December 31, 2023100,666 
Pension benefits paid(6,216)
Foreign exchange gains(1,237)
Return on plan assets(4,727)
Balance at December 29, 2024$88,486 
 
With respect to plans outside of the United States, the Company expects to contribute $6.8 million in the aggregate during fiscal year 2025.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
 
Non-U.S.U.S.
(In thousands)
2025$12,813 $8,298 
202612,891 8,273 
202712,817 8,228 
202813,039 8,159 
202912,961 8,001 
2030-203365,156 36,400 
 
The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 29, 2024 and December 31, 2023, the projected benefit obligations were $16.4 million and $18.6 million, respectively. Assets with a fair value of $0.6 million, segregated in a trust (which is included in marketable securities in the Other assets, net, on the consolidated balance sheets), were available to meet this obligation as of each of December 29, 2024 and December 31, 2023. Pension income and expenses for this plan netted to income of $0.3 million in fiscal year 2024, expense of $1.5 million in fiscal year 2023 and income of $3.2 million in fiscal year 2022.
 
Post-retirement Medical Plan:  The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. The costs of this plan are not material and the net assets in the plan totaled $19.2 million and $18.5 million at December 29, 2024 and December 31, 2023, respectively.
v3.25.0.1
Contingencies
 12 Months Ended
Dec. 29, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $14.2 million and $14.1 million as of December 29, 2024 and December 31, 2023, respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company’s environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities, including product liability claims. Legal defense costs are recognized as incurred, and insurance recoveries are recognized when collection is probable. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at the reporting date, the total cost of resolving these contingencies at December 29, 2024 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.
v3.25.0.1
Stock Plans
 12 Months Ended
Dec. 29, 2024
Share-Based Payment Arrangement [Abstract]  
Stock Plans Stock Plans
Stock-Based Compensation:
 
The Company’s 2019 Incentive Plan (the “2019 Plan”) authorizes the issuance of stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Company’s compensation programs. The 2019 Plan replaced the Company’s 2009 Incentive Plan (the “2009 Plan”). Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Company’s compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan.
 
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units and stock grants, included in the Company’s consolidated statements of operations:
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Cost of product and service revenue$2,495 $4,224 $7,459 
Research and development expenses3,863 5,276 6,799 
Selling, general and administrative expenses31,451 31,910 37,260 
Total stock-based compensation expense$37,809 $41,410 $51,518 
The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $8.0 million in fiscal year 2024, $10.6 million in fiscal year 2023 and $12.8 million in fiscal year 2022. Stock-based compensation costs capitalized as part of inventory were immaterial in all periods presented.

Stock Options:    The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued.
 
The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
Risk-free interest rate4.1 %4.1 %2.3 %
Expected dividend yield0.3 %0.2 %0.2 %
Expected lives5 years5 years5 years
Expected stock volatility33.6 %32.7 %28.5 %

The following table summarizes stock option activity for the fiscal year ended December 29, 2024:
 
 Number
of
Shares		Weighted-
Average Exercise
Price
 (Shares in thousands)
Outstanding at beginning of year1,073 $133.28 
Granted316 105.91 
Exercised(117)65.77 
Canceled(68)163.53 
Forfeited(44)143.11 
Outstanding at end of year1,160 $130.50 
Exercisable at end of year719 $139.01 
 
The aggregate intrinsic value for outstanding and exercisable stock options at December 29, 2024 was $4.8 million with a weighted-average remaining contractual term of 3.2 years. At December 29, 2024, there were 1.2 million outstanding stock options that were vested and expected to vest in the future, with an aggregate intrinsic value of $6.8 million and a weighted-average remaining contractual term of 4.2 years.
 
The weighted-average grant-date fair value of options granted during fiscal years 2024, 2023 and 2022 was $37.85, $45.18, and $48.09 per share, respectively. The total intrinsic value of options exercised during fiscal years 2024, 2023 and 2022 was $4.9 million, $2.4 million, and $13.9 million, respectively. Cash received from option exercises for fiscal years 2024, 2023 and 2022 was $7.7 million, $4.3 million, and $14.1 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $9.8 million in fiscal year 2024, $9.1 million in fiscal year 2023 and $9.5 million in fiscal year 2022.
There was $11.5 million of total unrecognized compensation cost related to nonvested stock options granted as of December 29, 2024. This cost is expected to be recognized over a weighted-average period of 1.9 years.
Restricted Stock Awards:    The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued
employment. The fair value of the award at the time of the grant is expensed on a straight-line basis primarily in selling, general and administrative expenses over the vesting period, which is generally 3 years. Recipients of the restricted stock have the right to vote such shares and receive dividends.
 
The following table summarizes restricted stock award activity for the fiscal year ended December 29, 2024:
 
Number
of
Shares		Weighted-
Average
Grant-
Date Fair
Value
 (Shares in thousands)
Nonvested at beginning of year341 $149.98 
Granted153 106.93 
Vested(200)154.96 
Forfeited(19)144.59 
Nonvested at end of year275 $122.80 
 
The fair value of restricted stock awards vested during fiscal years 2024, 2023 and 2022 was $30.9 million, $31.5 million, and $32.8 million, respectively. The total compensation expense recognized related to the restricted stock awards was $22.3 million in fiscal year 2024, $28.3 million in fiscal year 2023 and $34.2 million in fiscal year 2022.
 
As of December 29, 2024, there was $17.6 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.8 years.
Employee Stock Purchase Plan:
In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Company’s Board of Directors (the “Board”) voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2024, the Company issued 14,339 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $99.62 per share. During fiscal year 2023, the Company issued 28,899 shares under this plan at a weighted-average price of $108.37 per share. During fiscal year 2022, the Company issued 30,818 shares under this plan at a weighted-average price of $134.05 per share. At December 29, 2024, there remains available for sale to employees an aggregate of 0.7 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.
v3.25.0.1
Stockholders' Equity
 12 Months Ended
Dec. 29, 2024
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Comprehensive Income:
The components of accumulated other comprehensive (loss) income consisted of the following:
 
Foreign
Currency
Translation
Adjustment,
net of tax		Unrecognized
Prior Service
Costs, net of
tax		Unrealized
(Losses)
Gains on
Securities,
net of tax		Accumulated
Other
Comprehensive
(Loss) Income
 (In thousands)
Balance, January 2, 2022$(161,810)$(842)$(40)$(162,692)
Current year change(284,854)44 5 (284,805)
Balance, January 1, 2023(446,664)(798)(35)(447,497)
Current year change80,172 — (181)79,991 
Reclassification to retained earnings90,814 — — 90,814 
Balance, December 31, 2023(275,678)(798)(216)(276,692)
Current year change(119,260)— (153)(119,413)
Balance, December 29, 2024$(394,938)$(798)$(369)$(396,105)

Stock Repurchases:
On April 27, 2023, the Company’s Board of Directors (the “Board”) authorized the Company to repurchase shares of common stock for an aggregate amount up to $600.0 million under a stock repurchase program (the “Repurchase Program”). On October 24, 2024, the Repurchase Program was terminated by the Board and the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a new stock repurchase program (the “New Repurchase Program”). No shares remain available for repurchase under the Repurchase Program due to its termination. The New Repurchase Program will expire on October 24, 2026 unless terminated earlier by the Board and may be suspended or discontinued at any time. During fiscal year 2024, the Company repurchased 1,820,296 shares of common stock under the Repurchase Program for an aggregate cost of $213.6 million. During fiscal year 2024, the Company repurchased 1,238,755 shares of common stock under the New Repurchase Program for an aggregate cost of $142.8 million. As of December 29, 2024, $857.2 million remained available for aggregate repurchases of shares under the New Repurchase Program.
Subsequent to fiscal year 2024, the Company repurchased 575,758 shares of common stock under the New Repurchase Program at an aggregate cost of $66.8 million.
In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company’s equity incentive plans. During fiscal year 2024, the Company repurchased 86,484 shares of common stock for this purpose at an aggregate cost of $9.8 million. During fiscal year 2023, the Company repurchased 103,144 shares of common stock for this purpose at an aggregate cost of $13.1 million. During fiscal year 2022, the Company repurchased 115,247 shares of common stock for this purpose at an aggregate cost of $18.1 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
 
Dividends:
The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2024, 2023 and 2022, resulting in an annual cash dividends of $0.28 per share for fiscal years 2024, 2023 and 2022. At December 29, 2024, the Company had accrued $8.6 million for a dividend declared in October 24, 2024 for the fourth quarter of fiscal year 2024 that was paid in February 2025. On January 23, 2025, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2025 that will be payable in May 2025. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.
v3.25.0.1
Derivatives And Hedging Activities
 12 Months Ended
Dec. 29, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities Derivatives and Hedging Activities
 
The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business.
In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statements of cash flows.
Principal hedged currencies include the Chinese Renminbi, British Pound, Euro and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $409.8 million at December 29, 2024 and $412.1 million at December 31, 2023, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2024, 2023 and 2022.
During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 29, 2024, the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €498.6 million. The unrealized foreign exchange (gains) losses recorded in AOCI related to the net investment hedge were $(31.7) million, $19.5 million and $(34.5) million during the fiscal years 2024, 2023 and 2022, respectively.
The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive income (loss) into interest and other expense, net within the next twelve months.
v3.25.0.1
Fair Value Measurements
 12 Months Ended
Dec. 29, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
 Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of December 29, 2024.
 The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
 Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
 The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 29, 2024 and December 31, 2023 classified in one of the three classifications described above:
 
 Fair Value Measurements at December 29, 2024 Using:
 Total Carrying
Value at December 29, 2024		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,413 $27,413 $— $— 
Foreign exchange derivative assets861 — 861 — 
Foreign exchange derivative liabilities(1,048)— (1,048)— 
Contingent consideration asset14,890 $— $— 14,890 
Contingent consideration liability(21,753)— — (21,753)
 Fair Value Measurements at December 31, 2023 Using:
 Total Carrying
Value at December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$13,913 $13,913 $— $— 
Foreign exchange derivative assets1,697 — 1,697 — 
Foreign exchange derivative liabilities(1,763)— (1,763)— 
Contingent consideration asset14,890 $— $— 14,890 
Contingent consideration liability(40,005)— — (40,005)
 
Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
Marketable securities - available for sale: Includes equity and mutual fund investments measured at fair value using the quoted market prices in active markets at the reporting date.
Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company’s consolidated balance sheet on a net basis and are recorded in other assets. As of both December 29, 2024 and December 31, 2023, none of the master netting arrangements involved collateral.
Level 3 Valuation Techniques: The Company’s Level 3 assets and liabilities are comprised of contingent consideration related to the sale of the Business (see Note 3) and acquisitions. For assets and liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 assets and liabilities.

Contingent consideration:    Contingent consideration is measured at fair value at the disposition or acquisition date using projected milestone dates, discount rates, volatility, probabilities of success and projected achievement of financial targets, including revenues of the acquired business in many instances. Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model.
The fair value of the contingent consideration asset was initially measured using a lattice model and recognized upon the sale of the Business on March 13, 2023. In accordance with the terms of the sale of the Business, the Company is entitled to receive up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive on a sale or other capital event related to the Business. Potential valuation adjustments may be made as additional information and market factors that impact the expected exit valuation of the Business becomes available, with the impact of such adjustments being recorded in the Company’s consolidated statements of operations. Adjustments to the fair value since initial recognition were not material.
A reconciliation of the beginning and ending Level 3 contingent consideration asset is as follows:
 (In thousands)
Balance at January 1, 2023$— 
Amount recognized upon the sale of the Business15,930 
Change in fair value (included within selling, general and administrative expenses)(1,040)
Balance at December 31, 202314,890 
Change in fair value (included within selling, general and administrative expenses)— 
Balance at December 29, 2024$14,890 
The fair values of contingent consideration liability are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets, with the impact of such adjustments being recorded in the consolidated statements of operations.

As of December 29, 2024, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods that are substantially all revenue-based considerations, of up to $75.9 million. The expected maximum earnout period for acquisitions with open contingency period is 6.9 years from December 29, 2024, and the remaining weighted average expected earnout period at December 29, 2024 was 4.3 years.

A reconciliation of the beginning and ending Level 3 contingent consideration liabilities is as follows: 
 (In thousands)
Balance at January 2, 2022(57,996)
Additions(4,961)
Amounts paid and foreign currency translation2,562 
Purchase accounting adjustments recognized to goodwill12,400 
Change in fair value (included within selling, general and administrative expenses)1,377 
Balance at January 1, 2023(46,618)
Amounts paid and foreign currency translation9,741 
Change in fair value (included within selling, general and administrative expenses)(3,128)
Balance at December 31, 2023(40,005)
       Amounts paid and foreign currency translation16,383 
Change in fair value (included within selling, general and administrative expenses)1,869 
Balance at December 29, 2024$(21,753)
Financial Instruments Not Recorded at Fair Value
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
The Company’s investments in U.S. treasury securities that were classified as held-to-maturity had a fair value of $688.7 million and a carrying value of $689.9 million as of December 31, 2023. If measured at fair value, the investments in U.S. treasury securities would be classified as Level 1.
The Company’s outstanding senior unsecured notes had an aggregate fair value of $2,765.5 million and aggregate carrying value of $3,151.5 million as of December 29, 2024. The Company’s outstanding senior unsecured notes had an
aggregate fair value of $3,474.5 million and aggregate carrying value of $3,889.3 million as of December 31, 2023. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements.
The Company’s other debt facilities, including the Company’s senior unsecured revolving credit facility, had an aggregate carrying value of $0.5 million and $10.3 million as of December 29, 2024 and December 31, 2023, respectively. The carrying value approximates fair value and were classified as Level 2.
v3.25.0.1
Leases (Notes)
 12 Months Ended
Dec. 29, 2024
Disclosure Text Block [Abstract]  
Leases [Text Block] Leases
Lessee Disclosures
The Company leases certain property and equipment under operating and finance leases. The Company’s leases have remaining lease terms of less than 1 year to 25 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company.
The components of lease expense were as follows:
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Operating lease cost$40,957 $47,738 $39,989 
Supplemental cash flow information related to leases was as follows:
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$33,198 $42,597 $37,488 
Right-of-use assets obtained in exchange for new lease obligations:
   Operating leases47,649 10,049 55,016 
Supplemental balance sheet information related to leases was as follows:
 December 29,
2024		December 31,
2023
 (In thousands, except lease term and discount rate)
Operating Leases:
Operating lease right-of-use assets$167,716 $155,083 
Operating lease liabilities included in Accrued expenses and other current liabilities$23,582 $32,906 
Operating lease liabilities151,505 132,747 
Total operating lease liabilities$175,087 $165,653 
Weighted Average Remaining Lease Term in Years
Operating leases8.27.2
Weighted Average Remaining Discount Rate
Operating leases4.7%3.8%
Lease costs from finance leases, short-term leases, variable lease costs and sub-lease income are not material.
Future payments of operating lease liabilities as of December 29, 2024 were as follows:
 (In thousands)
2025$31,198 
202630,359 
202728,536 
202823,737 
202918,871 
2030 and thereafter80,835 
Total lease payments213,536 
Less imputed interest(38,449)
    Total $175,087 
v3.25.0.1
Industry Segment and Geographic Area Information
 12 Months Ended
Dec. 29, 2024
Segment Reporting [Abstract]  
Industry Segment Information Industry Segment and Geographic Area Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The CODM of the Company is the Chief Executive Officer (“CEO”). The CEO evaluates the performance of its operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1.
The principal products and services of the Company’s two reportable segments are:
•Life Sciences. Provides products and services targeted towards the life sciences customers.
•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the Company evaluates the performance of its segments is adjusted operating income, which consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, including primarily restructuring actions. The CODM does not evaluate operating segments using discrete asset information and there are no segment assets reported to the CODM. Accordingly, no segment assets have been reported.
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below for the fiscal years ended: 
December 29, 2024December 31, 2023January 1, 2023
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$1,254,145 $1,500,881 $2,755,026 $1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 
Segment cost of revenue421,035 644,143 431,883 628,001 418,833 710,040 
Segment selling, general and administrative expenses294,789 380,292 280,585 388,638 282,977 399,545 
Segment research and development expenses90,300 104,082 90,523 121,491 87,856 128,157 
Segment operating income$448,021 $372,364 820,385 $489,349 $320,101 809,450 $503,243 $781,171 1,284,414 
Corporate expenses(41,754)(40,417)(73,431)
Amortization of intangible assets(359,376)(365,113)(370,638)
Purchase accounting adjustments908 (5,129)(44,867)
Acquisition and divestiture-related costs(25,379)(69,159)(39,826)
Asset impairment(22,814)— — 
Significant litigation matters and settlements(7,775)(12)627 
Significant environmental matters— (2,457)— 
Restructuring and other, net(17,454)(26,601)(13,580)
Interest and other expense, net(30,615)(117,586)(90,862)
Income from continuing operations before income taxes$316,126 $182,976 $651,837 

Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
 Depreciation Expense
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Life Sciences$30,128 $30,110 $24,511 
Diagnostics36,074 33,994 29,942 
Corporate2,271 2,551 1,908 
Total depreciation expense$68,473 $66,655 $56,361 
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 29, 2024 and net long-lived assets based on physical location as of December 29, 2024 and December 31, 2023:
 Revenue
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
U.S.$1,097,856 $1,117,654 $1,546,520 
International:
China450,007 454,426 476,366 
United Kingdom112,883 125,419 136,017 
Other international1,094,280 1,053,072 1,152,919 
Total international1,657,170 1,632,917 1,765,302 
Total revenue$2,755,026 $2,750,571 $3,311,822 
 
 
Net Long-Lived Assets(1)
 December 29,
2024		December 31,
2023
 (In thousands)
U.S.$348,868 $317,226 
International:
Germany134,713 158,228 
China49,207 59,602 
Other international213,092 223,820 
Total international397,012 441,650 
Total net long-lived assets$745,880 $758,876 
(1) Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment and other long-term assets.
v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Pay vs Performance Disclosure      
Net income $ 270,385 $ 693,094 $ 569,179
v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 29, 2024
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement During the three months ended December 29, 2024, none of our directors or officers adopted a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as the terms are defined in Item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 29, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Disclosures
 We have developed and maintain a Material Cyber Incident Disclosure Program. The program includes processes for the identification, review and assessment of materiality of cyber events, notification of our senior leadership and Board of Directors of such events, and financial reporting disclosure where applicable. As part of the program, we also engage in due diligence regarding the cybersecurity capabilities of our current and potential third-party vendors in accordance with industry best practices. Under the program, all material cyber incidents will be reported to our Board of Directors. The program is led by our Cyber Event Disclosure Committee, which includes members of our Information Security, Corporate Legal, External Reporting and Enterprise Risk Management teams. In addition to assessing our own cybersecurity preparedness, we also consider and evaluate cybersecurity risks associated with use of third-party service providers. Our Internal Audit team conducts an annual review of third-party hosted applications with a specific focus on any sensitive data shared with third parties. For all critical third party service provides, we perform a review of the vendor's System and Organization Controls (SOC), which is referred to as a SOC 1 or SOC 2 report. If a third-party vendor is not able to provide a SOC 1 or SOC 2 report, we take additional steps to understand and mitigate any additional risks. Our assessment of risks associated with use of third-party providers is part of our overall risk management framework. We have implemented comprehensive cybersecurity initiatives for our employees, including education, training, and testing. These measures are conducted annually to ensure our employees remain up-to-date with the latest security practices, complementing our continuously improving processes and systems.
Our Chief Information Officer is responsible for developing and implementing our information security program. Our Information Security team monitors our exposure to external cybersecurity threats, leveraging automated tools and manual processes to ensure cybersecurity risk is effectively mitigated on a continuous basis. This team leverages internal IT resources, a managed security service provider, and additional third-party security software and technology services. When a specific incident has been identified, the Information Security team leverages our Cyber Incident Response Plan in conjunction with established Information Security policies to begin assessment of the incident. Depending on the type and/or severity of the incident, our Information Security team will determine (in compliance with our Cyber Incident Response Plan) whether third party expertise or consultation is necessary. If such expertise or consultation is determined to be necessary, our Information Security and Corporate Legal teams will engage with third-party experts. As part of its review of incidents, our Information Security team considers the risk exposure, potential impact, severity and implications with respect to our information technology systems. Our Information Security team is responsible for escalating incidents which are determined to be higher risk to our Cyber Event Disclosure Committee. The Cyber Event Disclosure Committee will work with our General Counsel to determine the materiality of the incident and any required disclosure. When an incident is determined to be material and is required to be disclosed, the Cyber Event Disclosure Committee will notify our senior leadership and our Board of Directors through the Audit Committee of our Board of Directors. The Cyber Event Disclosure Committee will collaborate with our Corporate Legal and Financial Reporting teams to develop any required Form 8-K Item 1.05 disclosure.
The oversight, monitoring, and testing of the program occurs under our Sarbanes-Oxley entity-level control reviews and the program is integrated into our Enterprise Risk Management processes. The Cyber Event Disclosure Committee convenes, at least monthly, to review recent developments in cybersecurity and in the cybersecurity risk landscape. The Cyber Event Disclosure Committee is comprised of representatives with relevant expertise for assessing and managing the applicable risks. Our Board of Directors is presented with updates on an annual, or as needed, basis regarding our cybersecurity preparedness. Additionally, our Board of Directors is provided with a comprehensive cyber training from our Chief Information Security Officer at least annually. Our Board of Directors annually reviews our cybersecurity program and the Audit Committee of our Board of Directors is specifically responsible for oversight of cybersecurity risk, which it regularly reviews with Company leadership.
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.
Cybersecurity Risk Board of Directors Oversight [Text Block] Our Information Security team is responsible for escalating incidents which are determined to be higher risk to our Cyber Event Disclosure Committee. The Cyber Event Disclosure Committee will work with our General Counsel to determine the materiality of the incident and any required disclosure. When an incident is determined to be material and is required to be disclosed, the Cyber Event Disclosure Committee will notify our senior leadership and our Board of Directors through the Audit Committee of our Board of Directors. The Cyber Event Disclosure Committee will collaborate with our Corporate Legal and Financial Reporting teams to develop any required Form 8-K Item 1.05 disclosure.
The oversight, monitoring, and testing of the program occurs under our Sarbanes-Oxley entity-level control reviews and the program is integrated into our Enterprise Risk Management processes. The Cyber Event Disclosure Committee convenes, at least monthly, to review recent developments in cybersecurity and in the cybersecurity risk landscape. The Cyber Event Disclosure Committee is comprised of representatives with relevant expertise for assessing and managing the applicable risks. Our Board of Directors is presented with updates on an annual, or as needed, basis regarding our cybersecurity preparedness. Additionally, our Board of Directors is provided with a comprehensive cyber training from our Chief Information Security Officer at least annually. Our Board of Directors annually reviews our cybersecurity program and the Audit Committee of our Board of Directors is specifically responsible for oversight of cybersecurity risk, which it regularly reviews with Company leadership.
Cybersecurity Risk Role of Management [Text Block] Our Board of Directors annually reviews our cybersecurity program
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cyber Event Disclosure Committee, which includes members of our Information Security, Corporate Legal, External Reporting and Enterprise Risk Management teams.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our Information Security team monitors our exposure to external cybersecurity threats, leveraging automated tools and manual processes to ensure cybersecurity risk is effectively mitigated on a continuous basis. This team leverages internal IT resources, a managed security service provider, and additional third-party security software and technology services. When a specific incident has been identified, the Information Security team leverages our Cyber Incident Response Plan in conjunction with established Information Security policies to begin assessment of the incident. Depending on the type and/or severity of the incident, our Information Security team will determine (in compliance with our Cyber Incident Response Plan) whether third party expertise or consultation is necessary. If such expertise or consultation is determined to be necessary, our Information Security and Corporate Legal teams will engage with third-party experts.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] The Cyber Event Disclosure Committee will work with our General Counsel to determine the materiality of the incident and any required disclosure. When an incident is determined to be material and is required to be disclosed, the Cyber Event Disclosure Committee will notify our senior leadership and our Board of Directors through the Audit Committee of our Board of Directors.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.0.1
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)
 12 Months Ended
Dec. 29, 2024
Accounting Policies [Abstract]  
Consolidation [Policy Text Block] The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In March 2023, the Company completed the sale of certain assets and the equity interests of certain entities constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”). The Business is reported for all periods as discontinued operations in the Company’s consolidated financial statements.
Fiscal Periods [Policy Text Block]
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a
52/53-week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 29, 2024 (“fiscal year 2024”), December 31, 2023 (“fiscal year 2023”) and January 1, 2023 (“fiscal year 2022”) included 52 weeks. The fiscal year ending December 28, 2025 (“fiscal year 2025”) will include 52 weeks.
Accounting Policies and Estimates [Policy Text Block]
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block]
Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers.
Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue.
The Company reports shipping and handling revenue in revenue, to the extent it is billed to customers, and the associated costs in cost of product revenue.
Inventories [Policy Text Block]
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense.
The Company is subject to the Global Intangible Low Taxed Income (“GILTI”) tax in the U.S. The Company elected to treat taxes on future GILTI inclusions in U.S. taxable income as a current period expense when incurred.
The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income.
Property, Plant and Equipment [Policy Text Block]
Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings - 10 to 40 years; leasehold improvements - estimated useful life or remaining term of lease, whichever is shorter; and machinery, equipment and capitalized internal-use software - 3 to 10 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. The Company capitalizes certain qualified costs incurred in connection with the development of internal-use software. The Company evaluates the costs incurred during the application development stage of internal use software to determine whether the costs meet the criteria for capitalization. Costs related to preliminary project activities and post implementation activities are expensed as incurred.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block] Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company’s fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies [Policy Text Block] Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income (“AOCI”), a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net
Business Combinations [Policy Text Block]
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses. Measurement period adjustments are made in the period in which the amounts are determined, and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]
Goodwill and Other Intangible Assets:  The Company’s intangible assets consist of (i) goodwill, which is not being amortized; and (ii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. During the fourth quarter of fiscal year 2024, the Company voluntarily changed its annual goodwill impairment testing date from the later of January 1 or the first day of each fiscal year to the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. The Company changed the measurement date to more closely align the annual impairment testing date with the most current information from the budgeting and strategic planning process. The Company believes the change in goodwill impairment testing date does not represent a material change to the Company’s method of applying an accounting principle in light of the Company’s internal controls and requirements to assess goodwill impairment upon certain triggering events. This change was applied prospectively and
therefore, the Company performed its annual impairment testing for its reporting units for fiscal year 2024 as of January 1, 2024 and November 1, 2024. The Company concluded that there was no goodwill impairment in the periods presented.
Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values.
Stock-Based Compensation [Policy Text Block] Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model or the quoted price of the Company’s stock on the grant date. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation.
Marketable Securities and Investments [Policy Text Block] Marketable Securities and Investments:  Investments in debt securities that are classified as available for sale are recorded at fair value with unrealized gains and losses included in AOCI until realized. Investments in debt securities that are classified as held-to-maturity are recorded at amortized cost. Investments in equity securities are recorded at fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair values are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred.
Cash Flows [Policy Text Block]
Cash and Cash Equivalents: The Company considers all highly liquid, unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block] Research and Development: Research and development costs are expensed as incurred.
Restructuring Charges [Policy Text Block] Restructuring and Other Costs: Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. The Company recorded restructuring charges, included in selling, general and administrative expenses in the consolidated statements of operations, of $17.5 million, $26.6 million and $13.6 million primarily associated with workforce reductions during fiscal years 2024, 2023 and 2022, respectively. The Company expects severance payments will be substantially completed during fiscal year 2025
New Accounting Pronouncement or Change in Accounting Principle, Description
Comprehensive Income:  Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded
as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements.
The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 will require public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The guidance is required to be applied on a prospective basis; retrospective application is permitted. The guidance is
effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.
In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 amends Accounting Standards Codification 280, Segment Reporting (“ASC 280”) to require public entities to disclose significant segment expenses and other segment items that are regularly provided to the chief operating decision maker (“CODM”) and included in each reported measure of a reportable segment’s profit or loss, on an annual and interim basis, and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 permits entities to report multiple measures of a reportable segment’s profit or loss if the CODM uses those measures to allocate resources and assess performance. The Company adopted the guidance in fiscal year 2024 and has included the additional disclosures related to the reportable segments in Note 21, Industry Segment and Geographic Area Information.
Lessee, Leases [Policy Text Block] Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
Lessor, Leases [Policy Text Block]
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
v3.25.0.1
Leases (Policies)
 12 Months Ended
Dec. 29, 2024
Leases [Abstract]  
Lessee, Leases [Policy Text Block] Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
Lessor, Leases [Policy Text Block]
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
v3.25.0.1
Revenue from Contract with Customer (Tables)
 12 Months Ended
Dec. 29, 2024
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue [Table Text Block]
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines.
Reportable Segments
For the fiscal year ended
December 29, 2024December 31, 2023January 1, 2023
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$659,444 $563,642 $1,223,086 $671,738 $543,875 $1,215,613 $683,170 $979,473 $1,662,643 
Europe283,256 459,358 742,614 308,567 438,457 747,024 297,468 534,343 831,811 
Asia311,445 477,881 789,326 312,035 475,899 787,934 312,271 505,097 817,368 
$1,254,145 $1,500,881 $2,755,026 $1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 
Major goods/service lines
Life Sciences reagents$719,268 $— $719,268 $732,789 $— $732,789 $691,344 $— $691,344 
Life Sciences instruments334,078 — 334,078 381,262 — 381,262 405,554 — 405,554 
Life Sciences software200,799 — 200,799 178,289 — 178,289 196,011 — 196,011 
Reproductive health— 523,931 523,931 — 501,302 501,302 — 516,574 516,574 
Applied genomics— 204,760 204,760 — 228,443 228,443 — 393,602 393,602 
Immunodiagnostics— 772,190 772,190 — 728,486 728,486 — 1,108,737 1,108,737 
$1,254,145 $1,500,881 $2,755,026 $1,292,340 $1,458,231 $2,750,571 $1,292,909 $2,018,913 $3,311,822 
v3.25.0.1
Discontinued Operations (Tables)
 12 Months Ended
Dec. 29, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] The following table summarizes the results of discontinued operations which are presented as income from discontinued operations in the Company’s consolidated statements of operations:
 December 29, 2024December 31, 2023January 1, 2023
 (In thousands)
Revenue$— $176,324 $1,298,376 
Cost of revenue— 125,219 859,330 
Selling, general and administrative expenses— 78,613 306,032 
Research and development expenses— 10,434 64,605 
Operating (loss) income— (37,942)68,409 
Other (loss) income:
(Loss) gain on sale(25,448)811,472 — 
Other (expense) income, net— (49)5,195 
Total other (loss) income(25,448)811,423 5,195 
(Loss) income from discontinued operations before income taxes(25,448)773,481 73,604 
(Benefit from) provision for income tax(12,762)259,890 17,101 
(Loss) income from discontinued operations$(12,686)$513,591 $56,503 
Schedule of Operating and Investing non-cash items from discontinued operations [Table Text Block]
The following operating and investing items from discontinued operations were as follows for the fiscal years ended:
December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Depreciation
$— $— $8,011 
Amortization
— — 16,984 
Capital expenditures— 1,292 10,670 
v3.25.0.1
Income Taxes (Tables) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
The components of income from continuing operations before income taxes were as follows for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
U.S.$134,177 $51,314 $326,438 
Non-U.S.181,949 131,662 325,399 
Total$316,126 $182,976 $651,837 
  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
The components of the provision for income taxes on continuing operations were as follows:
 
Current
Expense		Deferred 
Expense
(Benefit)		Total
(In thousands)
Fiscal year ended December 29, 2024
Federal$42,708 $(34,407)$8,301 
State17,040 (10,962)6,078 
Non-U.S.75,539 (56,863)18,676 
Total$135,287 $(102,232)$33,055 
Fiscal year ended December 31, 2023
Federal$39,800 $(60,845)$(21,045)
State9,183 (19,619)(10,436)
Non-U.S.78,154 (43,200)34,954 
Total$127,137 $(123,664)$3,473 
Fiscal year ended January 1, 2023
Federal$115,436 $(45,246)$70,190 
State27,757 (16,139)11,618 
Non-U.S.101,891 (44,538)57,353 
Total$245,084 $(105,923)$139,161 
  
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block]
The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: 
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Continuing operations$33,055 $3,473 $139,161 
Discontinued operations(12,762)259,890 17,101 
Total$20,293 $263,363 $156,262 
  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Tax at statutory rate$66,386 $38,346 $136,886 
Non-U.S. rate differential, net(13,332)(18,479)(5,221)
U.S. taxation of multinational operations(28,879)(4,594)22,102 
State income taxes, net2,174 (265)7,820 
Impact of rate changes— (12,795)— 
Prior year tax matters(9,389)3,971 (10,160)
Effect of stock compensation2,960 2,225 845 
General business tax credits(17,634)(4,718)(7,132)
Transfer pricing matters(2,391)(6,725)— 
Change in valuation allowance29,781 6,772 4,964 
Effect of foreign repatriations5,329 (4,737)(4,940)
Other, net(1,950)4,472 (6,003)
Total$33,055 $3,473 $139,161 
  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities were as follows: 
December 29,
2024		December 31,
2023
(In thousands)
Deferred tax assets:
Inventory$11,548 $12,934 
Reserves and accruals70,544 63,711 
Accrued compensation23,637 18,339 
Net operating loss and credit carryforwards176,504 133,919 
Accrued pension12,773 11,089 
Restructuring reserve1,369 1,588 
Deferred revenue18,388 17,539 
Capitalized research and development expenses69,208 47,188 
Operating lease liabilities33,468 29,319 
Unrealized foreign exchange loss
2,612 12,502 
All other, net775 1,610 
Total deferred tax assets420,826 349,738 
Deferred tax liabilities:
Postretirement health benefits(5,139)(4,452)
Depreciation and amortization(688,771)(784,925)
Operating lease right-of-use assets(30,881)(26,301)
Prepaid expenses(375)(349)
Deferred tax liability on foreign earnings(19,662)(17,587)
Total deferred tax liabilities(744,828)(833,614)
Valuation allowance(126,488)(84,626)
Net deferred tax liabilities$(450,490)$(568,502)
  
Components of net deferred tax asset recognized [Table Text Block]
The components of net deferred tax liabilities were recognized in the consolidated balance sheets as follows:
December 29,
2024		December 31,
2023
(In thousands)
Other assets, net$5,613 $8,158 
Deferred taxes and other long-term liabilities(456,103)(576,660)
Total$(450,490)$(568,502)
  
Deferred tax assets, other assets, net $ 5,613 $ 8,158
Deferred tax liabilities, Long-term liabilities (456,103) (576,660)
Deferred Tax Liabilities, Net $ (450,490) $ (568,502)
v3.25.0.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 29, 2024
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Number of common shares—basic122,756 124,704 126,155 
Effect of dilutive securities:
Stock options57 108 249 
Restricted stock awards9 — 22 
Number of common shares—diluted122,822 124,812 126,426 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact951 1,089 611 
v3.25.0.1
Accounts Receivable, Net Accounts Receivable, Net (Tables)
 12 Months Ended
Dec. 29, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Accounts receivable, net consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Accounts receivable, net$632,400 $632,811 
Long-term accounts receivable, net, included in Other assets, net28,163 29,593 
Total accounts receivable, net$660,563 $662,404 
Accounts Receivable, Allowance for Credit Loss
Reserves for credit losses consisted of the following:
Balance at Beginning of YearProvisionsCharges/
Write-offs
Other(1)
Balance at End
of Year
  (In thousands)
Year ended January 1, 2023$38,254 $9,857 $(9,672)$(896)$37,543 
Year ended December 31, 202337,543 9,067 (3,559)329 43,380 
Year ended December 29, 202443,380 9,715 (4,487)(636)47,972 
v3.25.0.1
Inventories, Net (Tables)
 12 Months Ended
Dec. 29, 2024
Inventory Disclosure [Abstract]  
Schedule of Net Inventories
Inventories, net consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Raw materials$174,502 $197,268 
Work in progress65,191 69,176 
Finished goods127,894 161,618 
Total inventories, net$367,587 $428,062 
v3.25.0.1
Property, Plant and Equipment, Net (Tables)
 12 Months Ended
Dec. 29, 2024
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment consisted of the following:
December 29,
2024		December 31,
2023
(In thousands)
At cost:
Land$29,521 $29,635 
Building and leasehold improvements364,556 358,380 
Machinery, equipment and capitalized internal-use software587,807 595,124 
Total property, plant and equipment981,884 983,139 
Accumulated depreciation(499,667)(473,485)
Total property, plant and equipment, net$482,217 $509,654 
v3.25.0.1
Marketable Securities and Investments (Tables)
 12 Months Ended
Dec. 29, 2024
Marketable Securities [Abstract]  
Schedule of Investments, Noncurrent [Table Text Block] Investments consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Marketable securities - held to maturity (current)$— $689,916 
Marketable securities - available for sale27,413 13,913 
Equity investments56,170 57,206 
Notes receivables and other investments12,337 12,280 
$95,920 $773,315 
Equity Securities without Readily Determinable Fair Value Equity investments, which are included in Other assets, net, as of December 29, 2024 and December 31, 2023 consisted of the following:
December 29,
2024		December 31,
2023
(In thousands)
Equity investments, carried at cost minus impairment, if any$46,460 $47,260 
Equity investments, carried at fair value9,710 9,946 
$56,170 $57,206 
v3.25.0.1
Goodwill and Intangible Assets, Net (Tables)
 12 Months Ended
Dec. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for fiscal years 2024 and 2023 are as follows:
Life SciencesDiagnosticsConsolidated
(In thousands)
Balance at January 1, 2023$4,551,575 $1,930,193 $6,481,768 
Foreign currency translation36,363 15,419 51,782 
Balance at December 31, 20234,587,938 1,945,612 6,533,550 
Foreign currency translation(46,471)(23,460)(69,931)
Balance at December 29, 2024$4,541,467 $1,922,152 $6,463,619 
Identifiable Intangible Asset Balances
Identifiable intangible asset balances at December 29, 2024 and December 31, 2023 were as follows:
December 29,
2024		December 31,
2023
(In thousands)
Patents$27,808 $27,811 
Less: Accumulated amortization(26,293)(26,072)
Net patents1,515 1,739 
Trade names and trademarks142,588 145,542 
Less: Accumulated amortization(87,824)(73,781)
Net trade names and trademarks54,764 71,761 
Licenses27,164 27,018 
Less: Accumulated amortization(17,855)(16,551)
Net licenses9,309 10,467 
Core technology1,561,831 1,582,458 
Less: Accumulated amortization(735,532)(607,814)
Net core technology826,299 974,644 
Customer relationships2,807,909 2,842,531 
Less: Accumulated amortization(1,058,875)(878,821)
Net customer relationships1,749,034 1,963,710 
Net amortizable intangible assets$2,640,921 $3,022,321 
v3.25.0.1
Debt (Tables)
 12 Months Ended
Dec. 29, 2024
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt [Table Text Block]
The following table summarizes the maturities of the Company’s indebtedness as of December 29, 2024: 
(In thousands)
2025$242 
2026521,781 
202781 
2028500,071 
2029850,000 
2030 and thereafter1,300,000 
Total debt payments$3,172,175 
Schedule of Debt The Company’s debt consisted of the following:
December 29, 2024
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,208)$(1,208)
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)521,700 (834)(780)520,086 
1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”)
500,000 (200)(2,408)497,392 
3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”)850,000 (1,448)(4,010)844,542 
2.55% Senior Unsecured Notes due in March 2031 (“March 2031 Notes”)400,000 (88)(2,294)397,618 
2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”)
500,000 (1,065)(3,059)495,876 
3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”)400,000 (4)(4,059)395,937 
Other Debt Facilities, non-current233 — — 233 
Total Long-Term Debt3,171,933 (3,639)(17,818)3,150,476 
Current Portion of Long-Term Debt:
Other Debt Facilities, current242 — — 242 
Total Current Portion of Long-Term Debt242 — — 242 
Total Debt$3,172,175 $(3,639)$(17,818)$3,150,718 
December 31, 2023
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,966)$(1,966)
2026 Notes553,450 (1,438)(1,279)550,733 
2028 Notes500,000 (250)(3,024)496,726 
2029 Notes850,000 (1,727)(4,781)843,492 
March 2031 Notes400,000 (101)(2,638)397,261 
September 2031 Notes500,000 (1,210)(3,568)495,222 
2051 Notes400,000 (4)(4,158)395,838 
Other Debt Facilities, non-current464 — — 464 
Total Long-Term Debt3,203,914 (4,730)(21,414)3,177,770 
Current Portion of Long-Term Debt:
0.850% Senior Unsecured Notes due in 2024 (“2024 Notes”)
711,479 (118)(1,301)710,060 
Other Debt Facilities, current11,812 — — 11,812 
Total Current Portion of Long-Term Debt723,291 (118)(1,301)721,872 
Total Debt$3,927,205 $(4,848)$(22,715)$3,899,642 
v3.25.0.1
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 29, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]
Accrued expenses and other current liabilities consisted of the following:
 
December 29,
2024		December 31,
2023
(In thousands)
Payroll and incentives$74,984 $50,526 
Employee benefits44,183 43,279 
Deferred revenue140,212 135,555 
Federal, non-U.S. and state income taxes74,403 88,159 
Operating lease liabilities
23,582 32,906 
Other accrued operating expenses128,031 174,045 
Total accrued expenses and other current liabilities$485,395 $524,470 
v3.25.0.1
Employee Benefit Plans (Tables) - Pension Plans, Defined Benefit
 12 Months Ended
Dec. 29, 2024
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Components of Net Periodic Benefit Cost (Credit) Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended:
December 29,
2024		December 31,
2023		January 1,
2023
(In thousands)
Service and administrative costs$5,017 $5,736 $6,331 
Interest cost17,008 19,585 10,751 
Expected return on plan assets(12,899)(14,600)(22,056)
Actuarial losses (gains)1,188 9,341 (23,706)
Net periodic pension cost (credit)$10,314 $20,062 $(28,680)
Schedule of Net Funded Status
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2024 and December 31, 2023.
 December 29, 2024December 31, 2023
Non-U.S.U.S.Non-U.S.U.S.
(In thousands)
Actuarial present value of benefit obligations:
Accumulated benefit obligations$212,120 $90,293 $227,174 $208,505 
Change in benefit obligations:
Projected benefit obligations at beginning of year$227,579 $208,505 $207,955 $231,492 
Service and administrative costs3,442 1,575 4,011 1,725 
Interest cost7,966 9,042 8,843 10,742 
Benefits paid and plan expenses(14,770)(20,986)(15,061)(39,895)
Plan settlements— (96,270)— — 
Actuarial losses (gains)(2,950)(11,573)12,871 4,441 
Effect of exchange rate changes(9,147)— 8,960 — 
Projected benefit obligations at end of year$212,120 $90,293 $227,579 $208,505 
Change in plan assets:
Fair value of plan assets at beginning of year$112,305 $202,331 $106,741 $216,748 
Actual return on plan assets(9,513)6,702 7,094 15,478 
Benefits paid and plan expenses(14,770)(20,986)(15,061)(39,895)
Employer’s contributions7,066 — 7,606 10,000 
Plan settlements— (96,270)— — 
Effect of exchange rate changes(1,588)— 5,925 — 
Fair value of plan assets at end of year$93,500 $91,777 $112,305 $202,331 
Net liabilities recognized in the consolidated balance sheets$(118,620)$1,484 $(115,274)$(6,174)
Net amounts recognized in the consolidated balance sheets consist of:
Other assets$7,552 $1,484 $19,540 $— 
Current liabilities(7,099)— (6,899)— 
Long-term liabilities(119,073)— (127,915)(6,174)
Net liabilities recognized in the consolidated balance sheets$(118,620)$1,484 $(115,274)$(6,174)
Actuarial assumptions as of the year-end measurement date:
Discount rate4.19 %5.71 %3.69 %4.54 %
Rate of compensation increase3.19 %None3.19 %None
Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
December 29, 2024December 31, 2023January 1, 2023
Non-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Discount rate3.69 %4.54 %4.12 %4.84 %1.41 %2.44 %
Rate of compensation increase3.19 %None3.16 %None2.78 %None
Expected rate of return on assets3.78 %4.60 %3.92 %4.80 %1.11 %7.25 %
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
December 29,
2024		December 31,
2023
(In thousands)
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
Projected benefit obligations$126,172 $134,814 
Fair value of plan assets— — 
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations$126,172 $134,409 
Fair value of plan assets— — 
Schedule of Allocation of Plan Assets Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 29, 2024 and December 31, 2023, and target asset allocations for fiscal year 2025 are as follows:
 Target AllocationPercentage of Plan Assets at
December 28, 2025December 29, 2024December 31, 2023
Asset CategoryNon-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Equity securities0-5%0-10%— %5 %— %6 %
Debt securities0-5%90-100%— %95 %— %94 %
Other95-100%0-10%100%— %100%— %
Total100 %100 %100 %100 %100 %100 %
Schedule of Changes in Fair Value of Plan Assets
The fair value of the Company’s pension plan assets as of December 29, 2024 and December 31, 2023 by asset category, classified in the three levels of inputs described in Note 19, Fair Value Measurements, are as follows:
 
 Fair Value Measurements at December 29, 2024 Using:
Total Carrying
Value at
December 29, 2024		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash and cash equivalents$7,555 $7,555 $— $— 
Equity securities:
U.S. large-cap3,049 3,049 — — 
International large-cap value887 887 — — 
Emerging markets growth403 403 — — 
Fixed income securities:
Corporate and U.S. debt instruments83,267 25,905 57,362 — 
Short-term corporate bonds1,630 — 1,630 — 
Other types of investments:
Foreign liability driven instrument88,486 — — 88,486 
Total assets measured at fair value$185,277 $37,799 $58,992 $88,486 
 Fair Value Measurements at December 31, 2023 Using:
Total Carrying
Value at
December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash$14,223 $14,223 $— $— 
Equity Securities:
U.S. large-cap7,011 7,011 — — 
International large-cap value2,350 2,350 — — 
Emerging markets growth1,068 1,068 — — 
Fixed income securities:
Corporate and U.S. debt instruments189,318 65,228 124,090 — 
Corporate bonds— — — — 
Other types of investments:
Foreign liability driven instrument100,666 — — 100,666 
Total assets measured at fair value$314,636 $89,880 $124,090 $100,666 
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets
A reconciliation of the beginning and ending Level 3 investments is as follows:
 
(In thousands)
Balance at January 1, 2023$95,062 
Pension benefits paid(6,051)
Foreign exchange losses5,957 
Return on plan assets5,698 
Balance at December 31, 2023100,666 
Pension benefits paid(6,216)
Foreign exchange gains(1,237)
Return on plan assets(4,727)
Balance at December 29, 2024$88,486 
Schedule of Expected Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
 
Non-U.S.U.S.
(In thousands)
2025$12,813 $8,298 
202612,891 8,273 
202712,817 8,228 
202813,039 8,159 
202912,961 8,001 
2030-203365,156 36,400 
v3.25.0.1
Stock Plans (Tables)
 12 Months Ended
Dec. 29, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Total Compensation Recognized Related to Outstanding Equity Awards
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units and stock grants, included in the Company’s consolidated statements of operations:
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Cost of product and service revenue$2,495 $4,224 $7,459 
Research and development expenses3,863 5,276 6,799 
Selling, general and administrative expenses31,451 31,910 37,260 
Total stock-based compensation expense$37,809 $41,410 $51,518 
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
 
December 29,
2024		December 31,
2023		January 1,
2023
Risk-free interest rate4.1 %4.1 %2.3 %
Expected dividend yield0.3 %0.2 %0.2 %
Expected lives5 years5 years5 years
Expected stock volatility33.6 %32.7 %28.5 %
Summary of Stock Option Activity
The following table summarizes stock option activity for the fiscal year ended December 29, 2024:
 
 Number
of
Shares		Weighted-
Average Exercise
Price
 (Shares in thousands)
Outstanding at beginning of year1,073 $133.28 
Granted316 105.91 
Exercised(117)65.77 
Canceled(68)163.53 
Forfeited(44)143.11 
Outstanding at end of year1,160 $130.50 
Exercisable at end of year719 $139.01 
Summary of Restricted Stock Award Activity
The following table summarizes restricted stock award activity for the fiscal year ended December 29, 2024:
 
Number
of
Shares		Weighted-
Average
Grant-
Date Fair
Value
 (Shares in thousands)
Nonvested at beginning of year341 $149.98 
Granted153 106.93 
Vested(200)154.96 
Forfeited(19)144.59 
Nonvested at end of year275 $122.80 
v3.25.0.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 29, 2024
Stockholders' Equity Note [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive (loss) income consisted of the following:
 
Foreign
Currency
Translation
Adjustment,
net of tax		Unrecognized
Prior Service
Costs, net of
tax		Unrealized
(Losses)
Gains on
Securities,
net of tax		Accumulated
Other
Comprehensive
(Loss) Income
 (In thousands)
Balance, January 2, 2022$(161,810)$(842)$(40)$(162,692)
Current year change(284,854)44 5 (284,805)
Balance, January 1, 2023(446,664)(798)(35)(447,497)
Current year change80,172 — (181)79,991 
Reclassification to retained earnings90,814 — — 90,814 
Balance, December 31, 2023(275,678)(798)(216)(276,692)
Current year change(119,260)— (153)(119,413)
Balance, December 29, 2024$(394,938)$(798)$(369)$(396,105)
v3.25.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 29, 2024
Fair Value Disclosures [Abstract]  
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 29, 2024 and December 31, 2023 classified in one of the three classifications described above:
 
 Fair Value Measurements at December 29, 2024 Using:
 Total Carrying
Value at December 29, 2024		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,413 $27,413 $— $— 
Foreign exchange derivative assets861 — 861 — 
Foreign exchange derivative liabilities(1,048)— (1,048)— 
Contingent consideration asset14,890 $— $— 14,890 
Contingent consideration liability(21,753)— — (21,753)
 Fair Value Measurements at December 31, 2023 Using:
 Total Carrying
Value at December 31, 2023		Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$13,913 $13,913 $— $— 
Foreign exchange derivative assets1,697 — 1,697 — 
Foreign exchange derivative liabilities(1,763)— (1,763)— 
Contingent consideration asset14,890 $— $— 14,890 
Contingent consideration liability(40,005)— — (40,005)
Reconciliation of Beginning and Ending Level 3 Net Liabilities
A reconciliation of the beginning and ending Level 3 contingent consideration liabilities is as follows: 
 (In thousands)
Balance at January 2, 2022(57,996)
Additions(4,961)
Amounts paid and foreign currency translation2,562 
Purchase accounting adjustments recognized to goodwill12,400 
Change in fair value (included within selling, general and administrative expenses)1,377 
Balance at January 1, 2023(46,618)
Amounts paid and foreign currency translation9,741 
Change in fair value (included within selling, general and administrative expenses)(3,128)
Balance at December 31, 2023(40,005)
       Amounts paid and foreign currency translation16,383 
Change in fair value (included within selling, general and administrative expenses)1,869 
Balance at December 29, 2024$(21,753)
v3.25.0.1
Leases (Tables)
 12 Months Ended
Dec. 29, 2024
Leases [Abstract]  
Lease, Cost [Table Text Block]
The components of lease expense were as follows:
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Operating lease cost$40,957 $47,738 $39,989 
Supplemental Cash Flow Information Related To Leases [Table Text Block]
Supplemental cash flow information related to leases was as follows:
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$33,198 $42,597 $37,488 
Right-of-use assets obtained in exchange for new lease obligations:
   Operating leases47,649 10,049 55,016 
Supplemental Balance Sheet Information Related To Leases [Table Text Block]
Supplemental balance sheet information related to leases was as follows:
 December 29,
2024		December 31,
2023
 (In thousands, except lease term and discount rate)
Operating Leases:
Operating lease right-of-use assets$167,716 $155,083 
Operating lease liabilities included in Accrued expenses and other current liabilities$23,582 $32,906 
Operating lease liabilities151,505 132,747 
Total operating lease liabilities$175,087 $165,653 
Weighted Average Remaining Lease Term in Years
Operating leases8.27.2
Weighted Average Remaining Discount Rate
Operating leases4.7%3.8%
Lease costs from finance leases, short-term leases, variable lease costs and sub-lease income are not material.
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
Future payments of operating lease liabilities as of December 29, 2024 were as follows:
 (In thousands)
2025$31,198 
202630,359 
202728,536 
202823,737 
202918,871 
2030 and thereafter80,835 
Total lease payments213,536 
Less imputed interest(38,449)
    Total $175,087 
v3.25.0.1
Industry Segment and Geographic Area Information (Tables)
 12 Months Ended
Dec. 29, 2024
Segment Reporting [Abstract]  
Schedule of Depreciation [Table Text Block]
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
 Depreciation Expense
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
Life Sciences$30,128 $30,110 $24,511 
Diagnostics36,074 33,994 29,942 
Corporate2,271 2,551 1,908 
Total depreciation expense$68,473 $66,655 $56,361 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 29, 2024 and net long-lived assets based on physical location as of December 29, 2024 and December 31, 2023:
 Revenue
 December 29,
2024		December 31,
2023		January 1,
2023
 (In thousands)
U.S.$1,097,856 $1,117,654 $1,546,520 
International:
China450,007 454,426 476,366 
United Kingdom112,883 125,419 136,017 
Other international1,094,280 1,053,072 1,152,919 
Total international1,657,170 1,632,917 1,765,302 
Total revenue$2,755,026 $2,750,571 $3,311,822 
 
 
Net Long-Lived Assets(1)
 December 29,
2024		December 31,
2023
 (In thousands)
U.S.$348,868 $317,226 
International:
Germany134,713 158,228 
China49,207 59,602 
Other international213,092 223,820 
Total international397,012 441,650 
Total net long-lived assets$745,880 $758,876 
v3.25.0.1
Business Combinations and Asset Purchases (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Business Acquisition [Line Items]      
Beginning balance $ 6,463,619 $ 6,533,550 $ 6,481,768
Sirion, Qognit, Sonovol and Prisms [Member]      
Business Acquisition [Line Items]      
Business Combination, Contingent Consideration Arrangements, Maximum Period 6 years 10 months 24 days    
Business Combination, Contingent Consideration Arrangements, Weighted Average Period 4 years 3 months 18 days    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 75,900    
Diagnostics [Member]      
Business Acquisition [Line Items]      
Beginning balance $ 1,922,152 $ 1,945,612 $ 1,930,193
v3.25.0.1
Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Business Acquisition [Line Items]      
Goodwill $ 6,463,619 $ 6,533,550 $ 6,481,768
Diagnostics [Member]      
Business Acquisition [Line Items]      
Goodwill $ 1,922,152 $ 1,945,612 $ 1,930,193
v3.25.0.1
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details)
$ in Millions
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jan. 01, 2023
USD ($)
Fiscal Year Week Format   52    
Restructuring and other costs, net   $ 17.5 $ 26.6 $ 13.6
New Date of Annual Goodwill Impairment Test   November 1, 2024    
Old Date of Annual Goodwill Impairment Test   January 1, 2024    
Minimum [Member] | Building [Member]        
Property, Plant and Equipment, Useful Life, Maximum   10 years    
Minimum [Member] | Tools, Dies and Molds [Member]        
Property, Plant and Equipment, Useful Life, Maximum   3 years    
Maximum [Member] | Building [Member]        
Property, Plant and Equipment, Useful Life, Maximum   40 years    
Maximum [Member] | Machinery and Equipment [Member]        
Property, Plant and Equipment, Useful Life, Maximum   10 years    
Subsequent Event [Member]        
Fiscal Year Week Format 52      
v3.25.0.1
Revenue from Contract with Customer (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Disaggregation of Revenue [Line Items]      
Segment revenue $ 2,755,026 $ 2,750,571 $ 3,311,822
Unbilled Receivables 80,600 75,800  
Customer Deposits in Advance of Transfer of Control, Current 19,500 22,100  
Deferred Revenue $ 212,800 209,700  
Remaining Performance Obligations Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.    
Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 1,223,086 1,215,613 1,662,643
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 742,614 747,024 831,811
Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 789,326 787,934 817,368
Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 1,500,881 1,458,231 2,018,913
Diagnostics [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue     330,700
Diagnostics [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage 10.00%    
Diagnostics [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 563,642 543,875 979,473
Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 459,358 438,457 534,343
Diagnostics [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 477,881 475,899 505,097
Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 1,254,145 1,292,340 1,292,909
Life Sciences [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 659,444 671,738 683,170
Life Sciences [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 283,256 308,567 297,468
Life Sciences [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 311,445 312,035 312,271
Life Sciences reagents [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 719,268 732,789 691,344
Life Sciences reagents [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Life Sciences reagents [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 719,268 732,789 691,344
Life Sciences instruments [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 334,078 381,262 405,554
Life Sciences instruments [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Life Sciences instruments [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 334,078 381,262 405,554
Life Sciences software [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 200,799 178,289 196,011
Life Sciences software [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Life Sciences software [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 200,799 178,289 196,011
Reproductive health [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 523,931 501,302 516,574
Reproductive health [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 523,931 501,302 516,574
Reproductive health [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Applied genomics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 204,760 228,443 393,602
Applied genomics [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 204,760 228,443 393,602
Applied genomics [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Immunodiagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 772,190 728,486 1,108,737
Immunodiagnostics [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 772,190 728,486 1,108,737
Immunodiagnostics [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 0 $ 0 $ 0
v3.25.0.1
Discontinued Operations Narrative (Details) - USD ($)
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Mar. 13, 2023
Aug. 01, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
(Benefit from) provision for income taxes on discontinued operations and dispositions $ (12,762,000) $ 259,890,000 $ 17,101,000    
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents 0 0 14,999,000    
Analytical, Food and Enterprise Services businesses          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Depreciation, Discontinued Operations 0 0 8,011,000    
Amortization, Discontinued Operations 0 0 16,984,000    
(Loss) gain on disposition of discontinued operations before income taxes (25,448,000) 811,472,000 0    
Disposal Group, Including Discontinued Operation, Consideration         $ 2,450,000,000
(Benefit from) provision for income taxes on discontinued operations and dispositions (12,762,000) 259,890,000 17,101,000    
Capital Expenditure, Discontinued Operations 0 $ 1,292,000 $ 10,670,000    
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks       $ 75,000,000.0  
Disposal Group, Consideration, Contingent on Exit Valuation       150,000,000.0  
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks, Recognized at Closing       65,200,000  
Disposal Group, including Discontinued Operations, Fair Value of Consideration, Contingent on Exit Valuation       15,900,000  
Disposal Group, including Discontinued Operations, Cash Received for Post-closing Adjustments 138,500,000        
Disposal Group, Consideration, Cash Proceeds at Closing       $ 2,270,000,000  
Disposal Group, including Discontinued Operations, Loss Related to Final Closing Statement 19,800,000        
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks, Received During the Period $ 18,800,000        
v3.25.0.1
Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Discontinued operations $ (12,762) $ 259,890 $ 17,101
Analytical, Food and Enterprise Services businesses      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Disposal Group, Including Discontinued Operation, Revenue 0 176,324 1,298,376
Disposal Group, Including Discontinued Operation, Costs of Goods Sold 0 125,219 859,330
Disposal Group, Including Discontinued Operation, General and Administrative Expense 0 78,613 306,032
Disposal Group, Including Discontinued Operations, Research and development expenses 0 10,434 64,605
Disposal Group, Including Discontinued Operation, Operating Income (Loss) 0 (37,942) 68,409
Income from discontinued operations before income taxes (25,448) 773,481 73,604
(Loss) gain on disposition of discontinued operations before income taxes (25,448) 811,472 0
Discontinued Operation, Other (Expense) Income, net 0 (49) 5,195
Discontinued Operation, Total Other (Expense) Income (25,448) 811,423 5,195
Discontinued operations (12,762) 259,890 17,101
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $ (12,686) $ 513,591 $ 56,503
v3.25.0.1
Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Income Tax Contingency [Line Items]      
Valuation Allowance, Amount $ 126,488 $ 84,626  
Unrecognized Tax Benefits [Roll Forward]      
Unrecognized tax benefits, beginning of period 129,056 57,948 $ 61,658
Gross increases - tax positions in prior period 29,623 64,697 1,489
Gross decreases - tax positions in prior period 0 0 (2,519)
Gross increases - current-period tax positions 0 14,969 7,187
Lapse of statute of limitations (7,251) (10,830) (8,625)
Foreign currency translation adjustments (1,643) 2,272 (1,242)
Unrecognized tax benefits, end of period   129,056 57,948
Income Tax Penalties and Interest Accrued 5,100 6,300  
Income Tax Penalties and Interest Expense 1,200 1,100 500
Unrecognized Tax Benefits, Ending Balance 149,785 129,056 57,948
Unrecognized Tax Benefits Expected To Be Resolved With In A Year 76,100    
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount 5,329 $ (4,737) $ (4,940)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 29,800    
General Business [Member]      
Unrecognized Tax Benefits [Roll Forward]      
Tax Credit Carryforward, Amount 24,700    
State and Local Jurisdiction [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards 6,200    
Unrecognized Tax Benefits [Roll Forward]      
Tax Credit Carryforward, Amount 11,800    
Foreign Tax Jurisdiction [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards 549,800    
Internal Revenue Service (IRS) [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards $ 104,900    
v3.25.0.1
Income Taxes Income Before Income taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Income Tax Contingency [Line Items]      
U.S. $ 134,177 $ 51,314 $ 326,438
Non-U.S. 181,949 131,662 325,399
Income from continuing operations before income taxes $ 316,126 $ 182,976 $ 651,837
v3.25.0.1
Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Income Tax Contingency [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount $ (13,332) $ (18,479) $ (5,221)
Federal current 42,708 39,800 115,436
Federal deferred expense (benefit) (34,407) (60,845) (45,246)
Federal total 8,301 (21,045) 70,190
State current 17,040 9,183 27,757
State deferred expense (benefit) (10,962) (19,619) (16,139)
State total 6,078 (10,436) 11,618
Non-U.S. current 75,539 78,154 101,891
Non-U.S.deferred expense benefit (56,863) (43,200) (44,538)
Non-U.S. total 18,676 34,954 57,353
Total current 135,287 127,137 245,084
Total deferred expense (benefit) (102,232) (123,664) (105,923)
Total 33,055 3,473 139,161
Discontinued operations (12,762) 259,890 17,101
Total provision for income taxes $ 20,293 $ 263,363 $ 156,262
v3.25.0.1
Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Income Tax Contingency [Line Items]      
Tax at statutory rate $ 66,386 $ 38,346 $ 136,886
Non-U.S. rate differential, net (13,332) (18,479) (5,221)
U.S. taxation of multinational operations (28,879) (4,594) 22,102
State income taxes, net 2,174 (265) 7,820
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 0 (12,795) 0
Prior year tax matters (9,389) 3,971 (10,160)
Effect of Stock Compensation 2,960 2,225 845
Federal tax credits (17,634) (4,718) (7,132)
Effective Income Tax Rate Reconciliation, Transfer Pricing Matters, Amount (2,391) (6,725) 0
Change in valuation allowance 29,781 6,772 4,964
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount 5,329 (4,737) (4,940)
Other, net (1,950) 4,472 (6,003)
Total $ 33,055 $ 3,473 $ 139,161
v3.25.0.1
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]    
Inventory $ 11,548 $ 12,934
Reserves and accruals 70,544 63,711
Accrued compensation 23,637 18,339
Net operating loss and credit carryforwards 176,504 133,919
Accrued pension 12,773 11,089
Restructuring reserve 1,369 1,588
Deferred revenue 18,388 17,539
Deferred Tax Assets, Capitalized Research and Development Costs 69,208 47,188
Deferred Tax Assets, Unrealized Foreign Exchange Losses 2,612 12,502
Deferred tax assets, operating lease liabilities 33,468 29,319
All other, net 775 1,610
Deferred Tax Assets, Gross 420,826 349,738
Postretirement health benefits (5,139) (4,452)
Depreciation and amortization (688,771) (784,925)
Deferred Tax Liabilities, Prepaid Expenses (375) (349)
Deferred tax liability on foreign earnings (19,662) (17,587)
Deferred tax liabilities, operating lease right-of-use assets (30,881) (26,301)
Total deferred tax liabilities (744,828) (833,614)
Valuation allowance (126,488) (84,626)
Deferred Tax Liabilities, Net (450,490) $ (568,502)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 29,800  
v3.25.0.1
Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]    
Valuation Allowance, Amount $ 126,488 $ 84,626
State and Local Jurisdiction [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 6,200  
Tax Credit Carryforward, Amount 11,800  
Foreign Tax Jurisdiction [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 549,800  
Internal Revenue Service (IRS) [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 104,900  
General Business [Member]    
Income Tax Contingency [Line Items]    
Tax Credit Carryforward, Amount $ 24,700  
v3.25.0.1
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Earnings Per Share [Abstract]      
Number of common shares-basic 122,756 124,704 126,155
Effect of dilutive securities, Stock options 57 108 249
Effect of dilutive securities, Restricted stock 9 0 22
Number of common shares-diluted 122,822 124,812 126,426
Number of potentially dilutive securities excluded from calculation due to antidilutive impact 951 1,089 611
v3.25.0.1
Accounts Receivable, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Accounts receivable, net $ 632,400 $ 632,811  
Accounts Receivable, after Allowance for Credit Loss, Noncurrent 28,163 29,593  
Accounts Receivable, after Allowance for Credit Loss 660,563 662,404  
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Accounts Receivable, Allowance for Credit Loss, Beginning Balance 43,380 37,543 $ 38,254
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 9,715 9,067 9,857
Accounts Receivable, Allowance for Credit Loss, Writeoff (4,487) (3,559) (9,672)
Accounts Receivable, Allowance for Credit Loss, Ending Balance 47,972 43,380 37,543
Allowance for Credit Loss [Abstract]      
Allowance for Credit Loss, Receivables, Other Period Activity $ (636) $ 329 $ (896)
v3.25.0.1
Inventories, Net (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 174,502 $ 197,268
Work in progress 65,191 69,176
Finished goods 127,894 161,618
Total inventories $ 367,587 $ 428,062
v3.25.0.1
Property, Plant and Equipment, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 981,884 $ 983,139  
Accumulated depreciation (499,667) (473,485)  
Total property, plant and equipment, net 482,217 509,654  
Depreciation expense 68,473 66,655 $ 56,361
Asset Impairment Charges 22,814 0 0
Diagnostics [Member]      
Property, Plant and Equipment [Line Items]      
Depreciation expense 36,074 33,994 $ 29,942
Land [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 29,521 29,635  
Building and leasehold Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 364,556 358,380  
Machinery, equipment and capitalized internal-use software [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 587,807 $ 595,124  
v3.25.0.1
Investments, Debt and Equity Securities (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Equity Securities without Readily Determinable Fair Value [Line Items]    
Marketable Securities, Noncurrent $ 27,413 $ 13,913
Equity Securities without Readily Determinable Fair Value, Amount 56,170 57,206
Equity investments, carried at cost minus impairment, if any 46,460 47,260
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 31,300 31,300
Equity Securities, FV-NI and without Readily Determinable Fair Value 9,710 9,946
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 7,100 5,000
Marketable securities - held to maturity (current) 0 $ 689,916
Investments in debt securities, Notional Amount, Due Within One to Five Years $ 300  
v3.25.0.1
Marketable Securities and Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Debt Securities, Available-for-sale [Line Items]      
Marketable Securities, Noncurrent $ 27,413 $ 13,913  
Marketable securities - held to maturity (current) 0 689,916  
Unrealized (losses) gains on securities, net of tax (153) (181) $ 5
Marketable Securities and Investments 95,920 773,315  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 7,100 5,000  
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 31,300 31,300  
Investments in debt securities 12,337 12,280  
Investments in debt securities, Notional Amount, Due Within One to Five Years 300    
Investments in debt securities, Convertible to Equity Securities or are due and payable upon event of default, Notional Amount 12,000    
Other than temporary impairment, included in Interest and other expense, net $ 1,800 $ 34,500  
v3.25.0.1
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Goodwill and Intangible Assets Net [Line Items]      
Total amortization expense related to finite-lived intangible assets $ 359,400 $ 365,100 $ 370,600
Future Amortization Expense, Year One 331,500    
Future Amortization Expense, Year Two 325,600    
Future Amortization Expense, Year Three 298,800    
Future Amortization Expense, Year Four 273,400    
Future Amortization Expense, Year Five 244,900    
Net amortizable intangible assets 2,640,921 3,022,321  
Beginning balance $ 6,463,619 6,533,550 6,481,768
Old Date of Annual Goodwill Impairment Test January 1, 2024    
Trade Names And Trademarks [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Net amortizable intangible assets $ 54,764 71,761  
Licenses [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Net amortizable intangible assets 9,309 10,467  
Diagnostics [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Beginning balance $ 1,922,152 $ 1,945,612 $ 1,930,193
v3.25.0.1
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance $ 6,533,550 $ 6,481,768
Foreign currency translation (69,931) 51,782
Ending balance 6,463,619 6,533,550
Life Sciences [Member]    
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance 4,587,938 4,551,575
Foreign currency translation (46,471) 36,363
Ending balance 4,541,467 4,587,938
Diagnostics [Member]    
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance 1,945,612 1,930,193
Foreign currency translation (23,460) 15,419
Ending balance $ 1,922,152 $ 1,945,612
v3.25.0.1
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Net amortizable intangible assets $ 2,640,921 $ 3,022,321
Intangible Assets, Net (Excluding Goodwill) 2,640,921 3,022,321
Patents [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,808 27,811
Less: Accumulated amortization (26,293) (26,072)
Net amortizable intangible assets 1,515 1,739
Trade Names And Trademarks [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 142,588 145,542
Less: Accumulated amortization (87,824) (73,781)
Net amortizable intangible assets 54,764 71,761
Licenses [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,164 27,018
Less: Accumulated amortization (17,855) (16,551)
Net amortizable intangible assets 9,309 10,467
Core Technology [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 1,561,831 1,582,458
Less: Accumulated amortization (735,532) (607,814)
Net amortizable intangible assets 826,299 974,644
Customer Relationships [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 2,807,909 2,842,531
Less: Accumulated amortization (1,058,875) (878,821)
Net amortizable intangible assets $ 1,749,034 $ 1,963,710
v3.25.0.1
Debt (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 29, 2024
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Jan. 07, 2025
Aug. 24, 2021
Unamortized Debt Issuance Expense $ 17,818   $ 17,818 $ 22,715      
Maturities of Long-term Debt [Abstract]              
2024 242   242        
2025 521,781   521,781        
2026 81   81        
2027 500,071   500,071        
2028 850,000   850,000        
2029 and Thereafter 1,300,000   1,300,000        
Long-term Debt Before Unamortized Discount 3,172,175   3,172,175        
Other Long-term Debt, Current 242   242 721,872      
Debt Instrument, Unamortized Discount 3,639   3,639 4,848      
Long-term Debt, Gross 3,171,933   3,171,933 3,203,914      
Debt, Long-term and Short-term, Combined Amount 3,172,175   3,172,175 3,927,205      
Current Portion of Long-Term Debt, Gross 242   242 723,291      
Current portion of long-term debt 242   242 721,872      
Proceeds from Sale and Maturity of Marketable Securities 710,000   710,000 550,000 $ 0    
Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (3,150,476)   (3,150,476) (3,177,770)      
Debt, Long-term and Short-term, Combined Amount 3,150,718   3,150,718 3,899,642      
Fair Value, Inputs, Level 1 [Member]              
Maturities of Long-term Debt [Abstract]              
Carrying value of Investments in US Treasury Securities measured at amortized cost (held-to-maturity)       689,900      
Long-term Debt              
Unamortized Debt Issuance Expense 17,818   17,818 21,414      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 3,639   3,639 4,730      
Long-term Debt - Current Portion [Member]              
Unamortized Debt Issuance Expense 0   0 1,301      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 0   0 118      
Line of Credit, Maturing September 17, 2024 [Member]              
Aggregate borrowings under the amended facility       0      
Unamortized Debt Issuance Expense       1,966      
Maturities of Long-term Debt [Abstract]              
Total       (1,966)      
Debt Instrument, Unamortized Discount       0      
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]              
Unamortized Debt Issuance Expense 4,010   4,010 4,781      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 1,448   1,448 1,727      
Long-term Debt, Gross 850,000   850,000 850,000      
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (844,542)   (844,542) (843,492)      
1.875 Percent Ten Year Senior Unsecured Notes [Member]              
Unamortized Debt Issuance Expense 780   780 1,279      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 834   834 1,438      
Long-term Debt, Gross 521,700   521,700 553,450      
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (520,086)   (520,086) (550,733)      
Line of Credit, Maturing August 24, 2026              
Unsecured revolving credit facility, amount             $ 1,500,000
Line of Credit Facility, Remaining Borrowing Capacity 1,500,000   1,500,000        
Letters of credit issued and outstanding 4,200   4,200        
Aggregate borrowings under the amended facility 0   0        
Unamortized Debt Issuance Expense 1,208   1,208        
Maturities of Long-term Debt [Abstract]              
Total (1,208)   (1,208)        
Debt Instrument, Unamortized Discount 0   $ 0        
Line of Credit, Maturing August 24, 2026 | Unsecured Revolving Credit Facility [Member] | Eurocurrency Rate [Member]              
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Basis Spread on Variable Rate     1.00%        
Line of Credit, Maturing August 24, 2026 | Unsecured Revolving Credit Facility [Member] | Federal Funds Rate [Member]              
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Basis Spread on Variable Rate     0.50%        
Line of Credit, Maturing January 7, 2030 [Member] | Subsequent Event [Member]              
Unsecured revolving credit facility, amount           $ 1,500,000  
Line of Credit, Maturing January 7, 2030 [Member] | Unsecured Revolving Credit Facility [Member] | Term Secured Overnight Financing Rate (SOFR) [Member] | Subsequent Event [Member]              
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Basis Spread on Variable Rate   1.00%          
Line of Credit, Maturing January 7, 2030 [Member] | Unsecured Revolving Credit Facility [Member] | Federal Funds Rate [Member] | Subsequent Event [Member]              
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Basis Spread on Variable Rate   0.50%          
0.550% Senior Unsecured Notes due 2023              
Unamortized Debt Issuance Expense       1,301      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount       118      
Current portion of long-term debt       711,479      
Repayments of Long-Term Debt     $ 711,500        
0.550% Senior Unsecured Notes due 2023 | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Current portion of long-term debt       710,060      
1.900% Senior Unsecured Notes due 2028              
Unamortized Debt Issuance Expense 2,408   2,408 3,024      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 200   200 250      
Long-term Debt, Gross 500,000   500,000 500,000      
1.900% Senior Unsecured Notes due 2028 | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (497,392)   (497,392) (496,726)      
2.55 Percent Senior Unsecured Notes due in 2031              
Unamortized Debt Issuance Expense 2,294   2,294 2,638      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 88   88 101      
Long-term Debt, Gross 400,000   400,000 400,000      
2.55 Percent Senior Unsecured Notes due in 2031 | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (397,618)   (397,618) (397,261)      
2.250% Senior Unsecured Notes due in 2031              
Unamortized Debt Issuance Expense 3,059   3,059 3,568      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 1,065   1,065 1,210      
Long-term Debt, Gross 500,000   500,000 500,000      
2.250% Senior Unsecured Notes due in 2031 | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (495,876)   (495,876) (495,222)      
3.625 Percent Senior Unsecured Notes due in 2051              
Unamortized Debt Issuance Expense 4,059   4,059 4,158      
Maturities of Long-term Debt [Abstract]              
Debt Instrument, Unamortized Discount 4   4 4      
Long-term Debt, Gross 400,000   400,000 400,000      
3.625 Percent Senior Unsecured Notes due in 2051 | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Total (395,937)   (395,937) (395,838)      
Other Debt Facilities - Non-current              
Unamortized Debt Issuance Expense 0   0 0      
Maturities of Long-term Debt [Abstract]              
Other Long-term Debt, Noncurrent 233   233 464      
Debt Instrument, Unamortized Discount 0   0 0      
Other Debt Facilities - Non-current | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Other Long-term Debt, Noncurrent 233   233 464      
Other Debt Facilities - Current              
Unamortized Debt Issuance Expense 0   0 0      
Maturities of Long-term Debt [Abstract]              
Other Long-term Debt, Current 242   242        
Debt Instrument, Unamortized Discount 0   0 0      
Current portion of long-term debt       11,812      
Other Debt Facilities - Current | Fair Value, Inputs, Level 2 [Member]              
Maturities of Long-term Debt [Abstract]              
Other Long-term Debt, Current $ 242   $ 242        
Current portion of long-term debt       $ 11,812      
v3.25.0.1
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Payroll and incentives $ 74,984 $ 50,526
Employee benefits 44,183 43,279
Deferred revenue 140,212 135,555
Federal, non-U.S. and state income taxes 74,403 88,159
Operating Lease liabilities, Accrued, Current 23,582 32,906
Other accrued operating expenses 128,031 174,045
Accrued expenses and other current liabilities $ 485,395 $ 524,470
v3.25.0.1
Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 5,017 $ 5,736 $ 6,331
Interest cost 17,008 19,585 10,751
Expected return on plan assets (12,899) (14,600) (22,056)
Actuarial loss (gain) 1,188 9,341 (23,706)
Net periodic benefit cost $ 10,314 $ 20,062 $ (28,680)
v3.25.0.1
Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation $ 126,172 $ 134,409    
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets 0 0    
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation 126,172 134,814    
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets 0 $ 0    
Other Pension Plan [Member]        
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Rate of Compensation Increase   3.19%    
Other Postretirement Benefit Plans, Defined Benefit [Member]        
Net amounts recognized in the consolidated balance sheets consist of:        
Net amounts recognized in the consolidated balance sheets 19,200 $ 18,500    
Foreign Plan [Member]        
Actuarial present value of benefit obligations: [Abstract]        
Accumulated benefit obligations 212,120 227,174    
Change in benefit obligations:        
Projected benefit obligations at beginning of year 227,579 207,955    
Service cost $ 3,442 $ 4,011    
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Long-term liabilities Long-term liabilities    
Actuarial loss (gain) $ (2,950) $ 12,871    
Effect of exchange rate changes (9,147) 8,960    
Projected benefit obligations at end of year 212,120 227,579 $ 207,955  
Change in plan assets:        
Fair value of plan assets at beginning of year 112,305 106,741    
Actual return on plan assets (9,513) 7,094    
Benefits paid and plan expenses (14,770) (15,061)    
Employer's contributions 7,066 7,606    
Defined Benefit Plan, Plan Assets, Payment for Settlement 0 0    
Effect of exchange rate changes (1,588) 5,925    
Fair value of plan assets at end of year 93,500 112,305 $ 106,741  
Net amounts recognized in the consolidated balance sheets consist of:        
Assets for Plan Benefits, Defined Benefit Plan 7,552 19,540    
Current liabilities (7,099) (6,899)    
Noncurrent liabilities (119,073) (127,915)    
Net amounts recognized in the consolidated balance sheets $ (118,620) $ (115,274)    
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Discount Rate 4.19% 3.69%    
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Rate of Compensation Increase 3.19%      
Defined Benefit Plan, Benefit Obligation, Benefits Paid $ 14,770 $ 15,061    
Defined Benefit Plan, Benefit Obligation, Payment for Settlement 0 0    
Defined Benefit Plan, Plan Assets, Payment for Settlement $ 0 $ 0    
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 3.69% 4.12% 1.41%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 3.19% 3.16% 2.78%  
Expected rate of return on assets   3.78% 3.92% 1.11%
UNITED STATES        
Actuarial present value of benefit obligations: [Abstract]        
Accumulated benefit obligations $ 90,293 $ 208,505    
Change in benefit obligations:        
Projected benefit obligations at beginning of year 208,505 231,492    
Service cost $ 1,575 $ 1,725    
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Long-term liabilities Long-term liabilities    
Actuarial loss (gain) $ (11,573) $ 4,441    
Effect of exchange rate changes 0 0    
Projected benefit obligations at end of year 90,293 208,505 $ 231,492  
Change in plan assets:        
Fair value of plan assets at beginning of year 202,331 216,748    
Actual return on plan assets 6,702 15,478    
Benefits paid and plan expenses (20,986) (39,895)    
Employer's contributions 0 10,000    
Defined Benefit Plan, Plan Assets, Payment for Settlement (96,270) 0    
Effect of exchange rate changes 0 0    
Fair value of plan assets at end of year 91,777 202,331 $ 216,748  
Net amounts recognized in the consolidated balance sheets consist of:        
Assets for Plan Benefits, Defined Benefit Plan 1,484 0    
Current liabilities 0 0    
Noncurrent liabilities 0 (6,174)    
Net amounts recognized in the consolidated balance sheets $ 1,484 $ (6,174)    
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Discount Rate 5.71% 4.54%    
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Rate of Compensation Increase 0.00% 0.00%    
Defined Benefit Plan, Benefit Obligation, Benefits Paid $ 20,986 $ 39,895    
Defined Benefit Plan, Benefit Obligation, Payment for Settlement (96,270) 0    
Defined Benefit Plan, Plan Assets, Payment for Settlement $ 96,270 $ 0    
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 4.54% 4.84% 2.44%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 0.00% 0.00% 0.00%  
Expected rate of return on assets   4.60% 4.80% 7.25%
v3.25.0.1
Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Defined Benefit Plan, Equity Securities 100.00% 100.00%
UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Defined Benefit Plan, Equity Securities 100.00% 100.00%
Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Minimum [Member] | Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Minimum [Member] | Debt Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 90.00%  
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 95.00%  
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 5.00%  
Maximum [Member] | Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 10.00%  
Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 5.00%  
Maximum [Member] | Debt Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 10.00%  
Other Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 100.00% 100.00%
Other Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 0.00% 0.00%
Debt Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 0.00% 0.00%
Debt Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 95.00% 94.00%
Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 0.00% 0.00%
Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 5.00% 6.00%
v3.25.0.1
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 185,277 $ 314,636  
Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,555 14,223  
Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,049 7,011  
Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 887 2,350  
Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 403 1,068  
Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 83,267 189,318  
Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,630 0  
Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 88,486 100,666  
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 37,799 89,880  
Fair Value, Inputs, Level 1 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,555 14,223  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,049 7,011  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 887 2,350  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 403 1,068  
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 25,905 65,228  
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 1 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 58,992 124,090  
Fair Value, Inputs, Level 2 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 57,362 124,090  
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,630 0  
Fair Value, Inputs, Level 2 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 88,486 100,666  
Fair Value, Inputs, Level 3 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 88,486 $ 100,666 $ 95,062
v3.25.0.1
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year $ 314,636  
Fair value of plan assets at end of year 185,277 $ 314,636
Foreign liability driven investment [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 100,666  
Fair value of plan assets at end of year 88,486 100,666
Equity Securities, Emerging Markets Growth [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 1,068  
Fair value of plan assets at end of year 403 1,068
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 100,666  
Fair value of plan assets at end of year 88,486 100,666
Fair Value, Inputs, Level 3 [Member] | Foreign liability driven investment [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 100,666 95,062
Defined Benefit Plan, Realized losses   5,957
Fair value of plan assets at end of year 88,486 100,666
Defined Benefit Plan, Unrealized Gains   5,698
Defined Benefit Plan, Realized Gains   (6,051)
Defined Benefit Plan, Foreign exchange losses (1,237)  
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held (4,727)  
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Pension Benefits Paid (6,216)  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 0  
Fair value of plan assets at end of year $ 0 $ 0
v3.25.0.1
Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details)
$ in Thousands
Dec. 29, 2024
USD ($)
Foreign Plan [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Expected contributions in next fiscal year $ 6,800
2018 12,813
2019 12,891
2020 12,817
2021 13,039
2022 12,961
2023-2026 65,156
UNITED STATES  
Defined Benefit Plan Disclosure [Line Items]  
2018 8,298
2019 8,273
2020 8,228
2021 8,159
2022 8,001
2023-2026 $ 36,400
v3.25.0.1
Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 5,017 $ 5,736 $ 6,331
Interest cost 17,008 19,585 10,751
Expected return on plan assets (12,899) (14,600) (22,056)
Actuarial loss (gain) (1,188) (9,341) 23,706
Net periodic benefit cost $ 10,314 $ 20,062 $ (28,680)
v3.25.0.1
Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Other Postretirement Benefit Plans, Defined Benefit [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Net amounts recognized in the consolidated balance sheets $ 19,200 $ 18,500
v3.25.0.1
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 185,277 $ 314,636  
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 37,799 89,880  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 58,992 124,090  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 88,486 100,666  
Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,555 14,223  
Cash [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,555 14,223  
Cash [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Cash [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,049 7,011  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,049 7,011  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 887 2,350  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 887 2,350  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 83,267 189,318  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 25,905 65,228  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 57,362 124,090  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,630 0  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,630 0  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 88,486 100,666  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 88,486 100,666 $ 95,062
Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 403 1,068  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 403 1,068  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0 $ 0  
v3.25.0.1
Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details)
$ in Thousands
Dec. 29, 2024
USD ($)
Foreign Plan [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 6,800
2018 12,813
2019 12,891
2020 12,817
2021 13,039
2022 12,961
2023-2026 65,156
UNITED STATES  
Defined Benefit Plan Disclosure [Line Items]  
2018 8,298
2019 8,273
2020 8,228
2021 8,159
2022 8,001
2023-2026 $ 36,400
v3.25.0.1
Employee Benefit Plans (Savings Plan) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation 100.00%    
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match 5.00%    
Defined Contribution Plan, 401(k) Savings Plan Expense $ 13.3 $ 15.0 $ 20.0
v3.25.0.1
Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($)
$ in Millions
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]      
Projected benefit obligation $ 16.4 $ 18.6  
Fair value of plan assets 0.6    
Pension expense (income) $ (0.3) $ 1.5 $ (3.2)
v3.25.0.1
Contingencies (Details)
$ in Millions
 12 Months Ended
Dec. 29, 2024
USD ($)
years
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Number of years over which estimated environmental cost will be paid | years 10  
Accrual For Management's estimate of cost of remediation of known environmental matters | $ $ 14.2 $ 14.1
v3.25.0.1
Stock Plans (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total income tax benefit recognized for stock-based compensation $ 8,000 $ 10,600 $ 12,800
Aggregate intrinsic value for stock options exercisable $ 4,800    
Weighted average remaining contractual term of options exercisable (in years) 3 years 2 months 12 days    
Number of shares vested and expected to vest in the future 1,200,000    
Aggregate intrinsic value of vested and expected to vest stock options $ 6,800    
Weighted average remaining contractual term for options vested and expected to vest 4 years 2 months 12 days    
Total pre-tax stock-based compensation expense $ 37,809 41,410 51,518
Restricted Stock Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of stock granted (per share) $ 106.93    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 19,000    
Fair value of restricted stock awards vested $ 30,900 31,500 32,800
Total pre-tax stock-based compensation expense 22,300 $ 28,300 $ 34,200
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted $ 17,600    
Shares/units granted 153,000    
Awards/units outstanding 275,000 341,000  
Weighted-average period for recognition of unrecognized compensation cost, years 1 year 9 months 18 days    
Option vesting period (in years) 3 years    
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized under plan 5,000,000.0    
Weighted-average grant-date fair value of stock granted (per share) $ 99.62 $ 108.37 $ 134.05
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date 95.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 10.00%    
Shares/units granted 14,339 28,899 30,818
Shares available for grant under employee stock purchase plan 700,000    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of options $ 37.85 $ 45.18 $ 48.09
Total intrinsic value of options exercised $ 4,900 $ 2,400 $ 13,900
Cash received from option exercises 7,700 4,300 14,100
Total pre-tax stock-based compensation expense 9,800 $ 9,100 $ 9,500
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted $ 11,500    
Weighted-average period for recognition of unrecognized compensation cost, years 1 year 10 months 24 days    
Option vesting period (in years) 3 years    
Stock Options Expiration Period After Date of Grant 7 years    
2019 Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized under plan     6,250,000
v3.25.0.1
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 37,809 $ 41,410 $ 51,518
Cost of sales [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 2,495 4,224 7,459
Research and development expenses [Member ]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 3,863 5,276 6,799
Selling, general and administrative and other expenses [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 31,451 $ 31,910 $ 37,260
v3.25.0.1
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Share-Based Payment Arrangement [Abstract]      
Risk-free interest rate 4.10% 4.10% 2.30%
Expected dividend yield 0.30% 0.20% 0.20%
Expected lives, years 5 years 5 years 5 years
Expected stock volatility 33.60% 32.70% 28.50%
v3.25.0.1
Stock Plans (Summary of Stock Option Activity) (Details)
shares in Thousands
 12 Months Ended
Dec. 29, 2024
$ / shares
shares
Stock option activity  
Shares outstanding at beginning of the year 1,073
Shares granted 316
Shares exercised (117)
Shares canceled (68)
Shares forfeited (44)
Shares outstanding at end of year 1,160
Shares exercisable at end of year 719
Number of shares vested and expected to vest in the future 1,200
Weighted-average price, outstanding at beginning of year (per share) | $ / shares $ 133.28
Weighted-average price, granted (per share) | $ / shares 105.91
Weighted-average price, exercised (per share) | $ / shares 65.77
Weighted-average price, canceled (per share) | $ / shares 163.53
Weighted-average price, forfeited (per share) | $ / shares 143.11
Weighted-average price, outstanding at end of year (per share) | $ / shares 130.50
Weighted-average price, exercisable at end of year (per share) | $ / shares $ 139.01
v3.25.0.1
Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member]
shares in Thousands
 12 Months Ended
Dec. 29, 2024
$ / shares
shares
Restricted stock award activity  
Nonvested at beginning of year | shares 341
Shares, granted | shares 153
Shares, vested | shares (200)
Shares, forfeited | shares (19)
Nonvested at end of year | shares 275
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares $ 149.98
Weighted-average grant-date fair value of stock granted (per share) | $ / shares 106.93
Weighted-average grant-date fair value, vested (per share) | $ / shares 154.96
Weighted-average grant-date fair value, forfeited (per share) | $ / shares 144.59
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares $ 122.80
v3.25.0.1
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 2 Months Ended 3 Months Ended 12 Months Ended
Feb. 21, 2025
Mar. 30, 2025
Dec. 29, 2024
Sep. 29, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Oct. 01, 2023
Jul. 02, 2023
Apr. 02, 2023
Jan. 01, 2023
Oct. 02, 2022
Jul. 03, 2022
Apr. 03, 2022
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
May 09, 2025
Feb. 07, 2025
Oct. 24, 2024
Apr. 27, 2023
Schedule of Stockholders' Equity [Line Items]                                          
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans                             86,484 103,144 115,247        
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans                             $ 9,800 $ 13,100 $ 18,100        
Cash dividends (per share)     $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 $ 0.28 $ 0.28        
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations                             $ 369,368 $ 392,302 $ 80,638        
Unrecognized prior service credit, net of tax                             0 $ 0 $ 44        
O2024Q4Dividends [Member]                                          
Schedule of Stockholders' Equity [Line Items]                                          
Dividends accrued     $ 8,600                       $ 8,600            
Dividends Payable, Date Declared     Oct. 24, 2024                                    
Repurchase Program, 04/27/2023                                          
Schedule of Stockholders' Equity [Line Items]                                          
Number of common stock repurchased in open market                             1,820,296            
Share Repurchase Program, Authorized, Amount                                         $ 600,000
Aggregate Cost of Repurchased Common Shares Under Repurchase Program                             $ 213,600            
Repurchase Program, 10/24/2024                                          
Schedule of Stockholders' Equity [Line Items]                                          
Number of common stock repurchased in open market                             1,238,755            
Share Repurchase Program, Remaining Authorized, Amount     $ 857,200                       $ 857,200            
Share Repurchase Program, Authorized, Amount                                       $ 1,000,000  
Aggregate Cost of Repurchased Common Shares Under Repurchase Program                             $ 142,800            
Subsequent Event [Member] | O2024Q4Dividends [Member]                                          
Schedule of Stockholders' Equity [Line Items]                                          
Dividends Payable, Date to be Paid, Year and Month                                     2025-02    
Subsequent Event [Member] | O2025Q1Dividends [Member]                                          
Schedule of Stockholders' Equity [Line Items]                                          
Cash dividends (per share)   $ 0.07                                      
Dividends Payable, Date Declared   Jan. 23, 2025                                      
Dividends Payable, Date to be Paid, Year and Month                                   2025-05      
Subsequent Event [Member] | Repurchase Program, 10/24/2024                                          
Schedule of Stockholders' Equity [Line Items]                                          
Number of common stock repurchased in open market 575,758                                        
Aggregate Cost of Repurchased Common Shares Under Repurchase Program $ 66,800                                        
v3.25.0.1
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Cumulative Translation Adjustment Summary [Roll Forward]        
Foreign currency translation adjustment, net of tax, beginning of year $ (275,678) $ (446,664) $ (161,810)  
Current year change (119,260) 80,172 (284,854)  
Foreign currency translation adjustment, net of tax, end of year (394,938) (275,678) (446,664)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax   90,814    
Foreign currency translation adjustments, net of income taxes, reclassified to earnings 0   0  
Foreign currency translation adjustment, net of tax, Reclassification to Retained Earnings   90,814    
Unrecognized prior service costs, net of tax, reclassification to retained earnings   0    
Unrealized (losses) gains on securities, net of tax, reclassification to retained earnings   0    
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax (119,413) 170,805 (284,805)  
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (119,413) 79,991 (284,805)  
Unrecognized prior service costs, net of tax (798) (798) (798) $ (842)
Unrecognized prior service costs, net of tax, current year change 0 0 44  
Unrealized (losses) gains on securities, net of tax (369) (216) (35) (40)
Unrealized (losses) gains on securities, net of tax, current year change (153) (181) 5  
Accumulated other comprehensive income (loss) $ (396,105) $ (276,692) $ (447,497) $ (162,692)
v3.25.0.1
Derivatives And Hedging Activities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Derivative [Line Items]      
Company's business conducted outside United States 60.00%    
Payments for (Proceeds from) Hedge, Financing Activities $ 0 $ 0 $ 762
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 0    
European And Asian Currencies [Member]      
Derivative [Line Items]      
Maximum maturity period for foreign exchange contracts, in months 12 months    
Duration of foreign currency derivative contract, days 30 days    
Fair Value Hedging [Member]      
Derivative [Line Items]      
Derivative, Notional Amount $ 409,800 412,100  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Derivative [Line Items]      
Foreign Currency Contract, Asset, Fair Value Disclosure (861) (1,697)  
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Net Investment Hedging [Member]      
Derivative [Line Items]      
Notional Amount of Nonderivative Instruments 498,600    
Unrealized Gain (Loss) on Net Investment Hedge in AOCI $ 31,700 $ (19,500) $ 34,500
v3.25.0.1
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Mar. 13, 2023
Jan. 01, 2023
Jan. 02, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 21,753 $ 40,005   $ 46,618 $ 57,996
Analytical, Food and Enterprise Services businesses          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Disposal Group, Consideration, Contingent on Exit Valuation     $ 150,000    
Senior Unsecured Notes          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Unsecured senior notes, fair value 2,765,500 3,474,500      
Sirion, Qognit, Sonovol and Prisms [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 75,900        
Business Combination, Contingent Consideration Arrangements, Maximum Period 6 years 10 months 24 days        
Business Combination, Contingent Consideration Arrangements, Weighted Average Period 4 years 3 months 18 days        
Fair Value, Inputs, Level 1 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Carrying value of Investments in US Treasury Securities measured at amortized cost (held-to-maturity)   689,900      
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 0 0      
Fair value of Investments in US Treasury Securities measured at amortized cost (held-to-maturity), classified as current   688,700      
Fair Value, Inputs, Level 2 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 3,150,476 3,177,770      
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0      
Fair Value, Inputs, Level 2 [Member] | Senior Unsecured Notes          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 3,151,500 3,889,300      
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities, including the senior revolving credit facility          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Other Long-term Debt $ 500 $ 10,300      
v3.25.0.1
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Jan. 02, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 21,753 $ 40,005 $ 46,618 $ 57,996
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 14,890 $ 0  
Fair Value, Recurring [Member] | Carrying Value [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities (27,413) (13,913)    
Foreign Currency Contract, Asset, Fair Value Disclosure 861 1,697    
Foreign exchange derivative liabilities, net (1,048) (1,763)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 21,753 40,005    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 14,890    
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities (27,413) (13,913)    
Foreign Currency Contract, Asset, Fair Value Disclosure 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0 0    
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign Currency Contract, Asset, Fair Value Disclosure 861 1,697    
Foreign exchange derivative liabilities, net (1,048) (1,763)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0 0    
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign Currency Contract, Asset, Fair Value Disclosure 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 21,753 40,005    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $ 14,890 $ 14,890    
v3.25.0.1
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Balance beginning of period $ (40,005) $ (46,618) $ (57,996)
Additions     (4,961)
Payments (16,383) (9,741) (2,562)
Adjustments Recognized in Goodwill     12,400
Change in fair value (included within selling, general and administrative expenses) 1,869 (3,128) 1,377
Balance end of period (21,753) (40,005) (46,618)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 14,890 $ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases   15,930  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) $ 0 $ (1,040)  
v3.25.0.1
Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Leases [Abstract]      
Operating Lease, Cost $ 40,957 $ 47,738 $ 39,989
Schedule Of Supplemental Cash Flow Information Related To Leases [Line Items]      
Operating Lease, Payments 33,198 42,597 37,488
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 47,649 $ 10,049 $ 55,016
v3.25.0.1
Leases Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating Lease, Right-of-Use Asset $ 167,716 $ 155,083
Operating Lease, Liability $ 175,087 $ 165,653
Operating Lease, Weighted Average Remaining Lease Term 8 years 2 months 12 days 7 years 2 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent 4.70% 3.80%
Other Current Liabilities [Member]    
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating lease liabilities included in Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued expenses and other current liabilities
Other Noncurrent Liabilities [Member]    
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating lease liabilities Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent
v3.25.0.1
Leases Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Operating Lease Liabilities, Maturity [Line Items]      
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months $ 31,198    
Lessee, Operating Lease, Liability, Payments, Due Year Two 30,359    
Lessee, Operating Lease, Liability, Payments, Due Year Three 28,536    
Lessee, Operating Lease, Liability, Payments, Due Year Four 23,737    
Lessee, Operating Lease, Liability, Payments, Due Year Five 18,871    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 80,835    
Operating Lease, Payments 33,198 $ 42,597 $ 37,488
Lessee, Operating Lease, Liability, Payments, Due 213,536    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (38,449)    
Operating Lease, Liability $ 175,087 $ 165,653  
v3.25.0.1
Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
USD ($)
segments
Dec. 31, 2023
USD ($)
Jan. 01, 2023
USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue $ 2,755,026 $ 2,750,571 $ 3,311,822
Number of Operating Segments | segments 2    
Interest and other expense (income), net $ (30,615) (117,586) (90,862)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 316,126 182,976 651,837
Asset Impairment Charges 22,814 0 0
Amortization of Intangible Assets 359,400 365,100 370,600
Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 2,755,026 2,750,571 3,311,822
Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment operating income 820,385 809,450 1,284,414
Reconciling Item (to Reconcile Segment Operating Income to Income from Continuing Operations before Income Taxes) [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Corporate Expenses (41,754) (40,417) (73,431)
Significant litigation matters and settlements (7,775) (12)  
Asset Impairment Charges (22,814) 0 0
Significant environmental matters $ 0 $ (2,457) $ 0
Restructuring and other, net Segment selling, general and administrative expenses Segment selling, general and administrative expenses Segment selling, general and administrative expenses
Amortization of Intangible Assets $ (359,376) $ (365,113) $ (370,638)
Purchase accounting adjustments 908 (5,129) (44,867)
Acquisition and divestiture-related costs (25,379) (69,159) (39,826)
Significant litigation matters and settlements, Income     627
Diagnostics [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,500,881 1,458,231 2,018,913
Segment operating income 372,364 320,101 781,171
Diagnostics [Member] | Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,500,881 1,458,231 2,018,913
Diagnostics [Member] | Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment Cost of Revenue 644,143 628,001 710,040
Segment Selling, general and administrative expenses 380,292 388,638 399,545
Segment research and development expenses 104,082 121,491 128,157
Asset Impairment Charges 22,800    
Life Sciences [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,254,145 1,292,340 1,292,909
Segment operating income 448,021 489,349 503,243
Life Sciences [Member] | Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,254,145 1,292,340 1,292,909
Life Sciences [Member] | Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment Cost of Revenue 421,035 431,883 418,833
Segment Selling, general and administrative expenses 294,789 280,585 282,977
Segment research and development expenses $ 90,300 $ 90,523 $ 87,856
v3.25.0.1
Industry Segment and Geographic Area Information Schedule of Depreciation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense $ 68,473 $ 66,655 $ 56,361
Life Sciences [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense 30,128 30,110 24,511
Diagnostics [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense 36,074 33,994 29,942
Corporate (Reconciling Item) [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense $ 2,271 $ 2,551 $ 1,908
v3.25.0.1
Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Schedule of Total Assets, by segment [Line Items]    
Assets $ 12,392,478 $ 13,564,665
v3.25.0.1
Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Sales by Geographic Area [Line Items]      
Segment revenue $ 2,755,026 $ 2,750,571 $ 3,311,822
UNITED STATES      
Sales by Geographic Area [Line Items]      
Segment revenue 1,097,856 1,117,654 1,546,520
CHINA      
Sales by Geographic Area [Line Items]      
Segment revenue 450,007 454,426 476,366
UNITED KINGDOM      
Sales by Geographic Area [Line Items]      
Segment revenue 112,883 125,419 136,017
Other International [Member]      
Sales by Geographic Area [Line Items]      
Segment revenue 1,094,280 1,053,072 1,152,919
Total international [Member]      
Sales by Geographic Area [Line Items]      
Segment revenue $ 1,657,170 $ 1,632,917 $ 1,765,302
v3.25.0.1
Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($)
$ in Thousands
Dec. 29, 2024
Dec. 31, 2023
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets $ 745,880 $ 758,876
UNITED STATES    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 348,868 317,226
GERMANY    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 134,713 158,228
CHINA    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 49,207 59,602
Other International [Member]    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 213,092 223,820
Total international [Member]    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets $ 397,012 $ 441,650